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Abstract
As technology improves, there is a push to minimize the cost of diagnostics as well as the cost of screening for
novel drugs in the pharmaceutical industry. There is no exception in clinical point-of-care settings, and quick,
fast, and inexpensive tests are needed to determine if patients require treatment or a change in dosage. The
most successful endeavor in the realm of microfluidics is the InkJet printer, invented in 19801. Other examples
of successful and developing microfluidic technology include polymerase chain reaction, high throughput
DNA sequencing, and point-of-care pathology. It is therefore reasonable that micro-scale, more thorough and
diagnostically relevant coagulation studies might be desired.
Several hurdles exist to miniaturizing large scale processes, which stem from flow in the laminar regime. For
example, on chip mixing is considered difficult since the Reynolds number reaches a limit so low that the fluid
will not mix with particles on different streamlines. The Microfluidic Multi-Surface Coagulation Assay
(µMCA) Chip introduces a novel way of recalcifying citrated whole blood on-chip, which simplifies the job of
the operator and allows faster determination of results. Simple diffusion and convection of small particles
combined with intuitive design make the design of this product not only functional but also inexpensive.
Previous coagulation studies merely test one pathway to coagulation, and many do so in a test tube rather than
under flow. The µMCA will test both intrinsic and extrinsic coagulation pathways under arterial shear rates,
making results from the device more relevant to diagnostics or patient-specific dosage of coagulants or
anticoagulants. In summary, the µMCA provides a streamlined and thorough way to measure patient specific
clotting abilities in physically relevant flow regimes.
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Dear Professors Fabiano and Diamond, 
 
 
Our group was presented with the task of creating a microfluidic device which would test 
coagulation on collagen, collagen + tissue factor, and collagen + kaolin surfaces using an input 
of citrated whole blood. We succeeded in designing a device that not only uses a novel kaolin 
+lipid + collagen surface but also achieved on chip recalcification of citrated blood. We have 
named our product the "Microfluidic Multi-Surface Coagulation Assay." Compared with other 
methods of testing coagulation in the market, our product is faster, more representative of 
coagulation in vivo, and also tests both intrinsic and extrinsic coagulation pathways. It is simple 
to use, as all the physician or doctor must do is pipette 1 mL of blood onto the chip, place it in 
the machine, and turn it on to get results within 5 minutes.  
 
With the total market estimated at 10 million per year, and a projected 10% initial market 
penetration, the Microfluidic Multi-Surface Coagulation Assay is expected to process 1 million 
samples per year. Within one year, the internal rate of return is estimated at 247% at the price of 
$100 per chip. The project has a net present value of $176,195,600 assuming 10 years of 
production. By the third year of production, the return on investment is expected to be 442%, 
suggesting a profitable project. 
 
 
Yours sincerely, 
 
 
 
 
  
Elizabeth Cummings   Vamsi Vuppala    Melissa Wang 
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Chapter 1: Abstract 
 As technology improves, there is a push to minimize the cost of diagnostics as well as 
the cost of screening for novel drugs in the pharmaceutical industry. There is no exception in 
clinical point-of-care settings, and quick, fast, and inexpensive tests are needed to determine if 
patients require treatment or a change in dosage. The most successful endeavor in the realm of 
microfluidics is the InkJet printer, invented in 19801. Other examples of successful and 
developing microfluidic technology include polymerase chain reaction, high throughput DNA 
sequencing, and point-of-care pathology. It is therefore reasonable that micro-scale, more 
thorough and diagnostically relevant coagulation studies might be desired. 
 Several hurdles exist to miniaturizing large scale processes, which stem from flow in the 
laminar regime. For example, on chip mixing is considered difficult since the Reynolds number 
reaches a limit so low that the fluid will not mix with particles on different streamlines. The 
Microfluidic Multi-Surface Coagulation Assay (µMCA) Chip introduces a novel way of 
recalcifying citrated whole blood on-chip, which simplifies the job of the operator and allows 
faster determination of results. Simple diffusion and convection of small particles combined 
with intuitive design make the design of this product not only functional but also inexpensive. 
 Previous coagulation studies merely test one pathway to coagulation, and many do so in 
a test tube rather than under flow. The µMCA will test both intrinsic and extrinsic coagulation 
pathways under arterial shear rates, making results from the device more relevant to diagnostics 
or patient-specific dosage of coagulants or anticoagulants. In summary, the µMCA provides a 
streamlined and thorough way to measure patient specific clotting abilities in physically 
relevant flow regimes.  
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Chapter 2: Introduction  
2.1 Overview 
 Knowing the clotting ability of individual patients is important for many reasons, 
including suggested dose of anticoagulants or the determination of possible bleeding disorders 
in trauma patients. Current tests such as the activated partial thromboplastin time, or aPTT 
exploit either the intrinsic and extrinsic pathway, and none test blood clotting under flow. 
Testing under flow simulates a realistic in vivo scenario and thus results obtained in this way are 
more meaningful. Chapter 3 describes methods that exist on the lab-scale to test blood clotting 
under flow via the intrinsic pathway by linking tissue factor bearing liposomes to collagen 
surfaces2.  
 As described in Chapter 4, during a coagulation event, many complex reactions occur in 
the blood, and the combination of these reactions defines the coagulation cascade. There are two 
pathways to coagulation: the intrinsic pathway and extrinsic pathway. The extrinsic pathway 
what occurs at the surface of an injury, where factor VII binds with tissue factor and initiates the 
coagulation process. The intrinsic pathway occurs when blood is exposed to a charged surface 
such as collagen, glass, or kaolin and coagulation ensues. Chapter 5 describes how the 
Microfluidic Multi-Surface Coagulation Assay Chip will provide a way to measure the 
functionality of both pathways to coagulation, again in a diagnostically relevant flow regime. 
There are several important markers to coagulation in the human body. The µMCA Chip 
measures platelet and fibrin accumulation. Activated platelets initiate the downstream cascade 
of reactions, and fibrin is the final stabilized product that creates a blood clot. Thus these 
proteins serve as excellent markers for the extent of coagulation.  
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 Microfluidic technology allows the determination of a large amount of data with a small 
amount of input reagents and space. The µMCA Chip, as described in detail in Chapter 5, not 
only provides 6 distinct data sets (platelet and fibrin levels over time on collagen, collagen + 
kaolin + lipids, collagen + tissue factor surfaces) but provides them faster than the current 
competition and in a more clinically relevant form. Blood flow in the device is run at arterial 
shear rates, mimicking in vivo conditions. 
 Chapters 6 and 7 outline the manufacture of the microfluidic chip and cartridge. The 
fabrication of microfluidic chips is relatively inexpensive due to the small volume of materials 
required per chip; however, there are several key steps in their manufacture. 
Polydimethylsiloxane, or PDMS, is used as a base material, since it is optically clear and inert. 
The chips will be made using a series of techniques-- photolithography and soft lithography. A 
robotic liquid handling system will deposit the surfaces on a glass microscope slide, which will 
then be adhered to the fabricated PDMS chip. The chip will be place on a plastic cartridge, 
which is filled with calcium buffer and a fluorescent dye by another robotic liquid handling 
system.  
 Since the µMCA is a medical device, it is regulated by the FDA and must be approved 
before being sold in the marketplace. This process is outlined in Chapter 8, along with product 
development, prototyping, and clinical trials. The Microfluidic Multi-Surface Coagulation 
Assay is a Class II clinical device, and must be approved before use with patients. 
 Chapter 3 discusses the market for the µMCA chip, including several key areas such as 
hospitals and pharmaceutical companies. The chip will be useful in hospitals for the time-
sensitive treatment of trauma patients who might have abnormal coagulation abilities as well as 
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heart attack patients and stroke patients. Additionally, the device will be useful for clinical trials 
and the development and FDA approval of novel anticoagulants or coagulants. Together these 
applications create an enormous marketplace with no competition that achieves the same 
functionality as the Microfluidic Multi-Surface Coagulation Assay Chip. 
 Chapter 9 involves a rigorous financial analysis- from costing the chip, operating 
assumptions, income and cash flow, and a payback period. The findings detail that the under the 
assumption of a sales price of $100 per cartridge, the Net Present Value of the product is 
roughly $176 M. This is an internal rate of return of approximately 247%. Taking into 
consideration discounts to hospitals and insurance companies, it is estimated the sales price 
would average around $30, which has a NPV of $45M and an IRR of 137.6%. 
2.2 Project Charter and Scope 
Project Name On-Site Clinical Testing of Citrated Blood Samples 
Project Champion Scott Diamond, PhD 
Project Leaders Elizabeth M. Cummings, Vamsi K. Vuppala, Melissa M. Wang 
Specific Goals Design and build a microfluidic device that measures the 
clotting ability of blood with respect to Ca2+, Mg2+, and Zn2+ on 
Collagen, Collagen and Tissue Factor, and Collagen and Kaolin 
surfaces. 
Project Scope In-scope: 
-Basic design of the microfluidic device 
-Define mixing processes 
-Define splitting processes 
-Manufacturing procedure 
-Economic analysis 
-Experiment with designs of microfluidic device 
Deliverables Business opportunity 
Market expansion 
Technical feasibility 
Manufacturing capability assessment 
Competitive product analysis 
Laboratory data analysis 
Timeline The product design and testing will take place over 3 months 
2.3 Innovation Map 
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The innovation map is a tool that is used to identify relations between aspects of the 
materials, product, product technology, and the voice of the customer. As discussed by Seider et 
al., an innovation map for a product contains six levels that are connected12. Innovation maps 
start with the materials and end with customer value proposition. These steps are: Materials 
Technology, Process/Manufacturing Technology, Product Technology, Technical 
Differentiation, Products, and Customer-Value Proposition. The innovation map for the 
Microfluidic Multi-Surface Coagulation Assay is shown in Figure 2.1. 
 
Figure 2.1: Innovation Map. The innovation map shows the new technologies used to provide value 
The innovation map in Figure 2.1 shows the Customer-Value Proposition that we are 
trying to solve using this point of care device. The goal is to create a low cost device with the 
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ability to produce more data in a shorter amount of time than the previously available options 
for our customers. These qualities affect the ability of coagulation tests to be used in trauma 
patients where fast and accurate data concerning the clotting ability of a patient is critical. The 
final point of care device consists of both the processing unit and the chip-cartridge 
combination.  
This device differentiates itself from other devices on the market by its ability to 
produce data involving both blood clotting pathways in a shorter amount of time. The chip-
cartridge is composed of PDMS soft polymer. Using soft lithography, robotic liquid handling, 
and oxygen plasma treatment throughout the manufacturing process, the finished device has 
bifurcated streams that pass over parallel surfaces triggering the different coagulation pathways. 
The processing unit uses CCD Cameras, LEDs, robotic liquid handlers, and a syringe pump to 
offer faster study times, which are critical for patient safety in trauma wards and are more 
efficient for pharmaceutical companies performing clinical studies for potentially life-saving 
drugs.  
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Chapter 3: Market Analysis  
3.1 Market for Microfluidic Multi-Surface Coagulation Assay 
The Microfluidic Multi-Surface Coagulation Assay has the potential to fulfill unmet 
needs in a variety of markets with the advantage of being able to test blood clotting under flow 
conditions that mimic both the intrinsic and extrinsic clotting pathways. The initial target 
markets for the device include clinical laboratories for pharmaceutical companies, 
biotechnology research groups, hospitals, and point-of-care treatment facilities. A detailed 
market breakdown can be found in Appendix 13.2. The total market is assumed to be 10 million 
devices per year, and at 10% market penetration, the Microfluidic Multi-Surface Coagulation 
Assay is estimated to process 1 million samples in the first year of product launch.  
3.1.1 Clinical Applications 
Clinical studies are ideal targets for early product adaptation because the same test is 
repeated multiple times for each participant in the trial. This market generates a predictable 
demand for the product. The market for anticoagulants is growing, and many major 
pharmaceutical corporations are pursuing different variations of anticoagulants within their 
pipelines. The anticoagulant Eliquis, developed by Bristol Myers-Squibb Co and Pfizer Inc., 
was approved by the FDA in December 2012 as a competitor against the newly released Xarelto 
from Johnson & Johnson and Bayer and Pradaxa from Boehringer Ingelheim. These three drugs 
from major pharmaceutical companies are indicators for further clinical trials down the road4. 
Currently, 1,895 clinical trials in the United States are related to conditions involving blood 
clotting including coagulation management and atrial fibrillation. Enrollment in clinical studies 
varies widely from hundreds to thousands of patients3. In a previous clinical trial for the 
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anticoagulant Warfarin, 30,000 samples were tested 11.The high volume of trials and the large 
number of devices that would be utilized make clinical trials a prime market for the 
Microfluidic Multi-Surface Coagulation Assay.  
3.1.2 Point-of-Care Applications 
 Hospitals are often early adapters of new medical devices and technology due to their 
established patient base and, in the case of the Microfluidic Multi-Surface Coagulation Assay, a 
wide potential for application. Point-of-Care (POC) testing is driven by the advantage of 
bringing diagnostic tests immediately to patients and providing accurate and prompt results with 
increased diagnostic efficiency. In the United States there are nearly 800,000 strokes and over 
900,000 heart attacks annually5, 6. For these patients, the Microfluidic Multi-Surface 
Coagulation Assay can provide accurate and vital information that would allow physicians to 
discern the proper treatment method. Additionally, patients who have suffered from heart 
attacks or strokes often require follow-up tests to monitor their condition or to assist in dosage 
determination or adjustment.  
 In cases of trauma or emergency care, testing speed and accuracy is even more critical. 
In 2010, 45.4 million emergency room visits were the result of injuries, with 4.047 million visits 
resulting from motor vehicle accidents7. Although not all of the patients who enter the 
emergency room after an injury or accident will need results from this device, even if only 10-
20 percent of patients needed to be tested for blood clotting, it would still amount to a demand 
for millions of tests in a single year.  
 
3.1.3 Additional Applications 
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Further markets for the Microfluidic Multi-Surface Coagulation Assay have been 
identified and can be considered in the future in order to significantly increase revenue. The 
Microfluidic Multi-Surface Coagulation Assay has great potential for research applications with 
the advantage of being able to easily test blood coagulation under flow. Additional use in 
diagnostics is possible for patients who do not produce enough clot-forming proteins, as in the 
case of hemophilia. Eventually, the Microfluidic Multi-Surface Coagulation Assay target 
market could include physician’s offices, operating rooms, and even nursing homes and other 
long term care facilities.  
3.2 Product Requirements 
The three potential market segments targeted include trauma, cardiovascular, and 
clinical markets. Working within these markets, the Microfluidic Multi-Surface Coagulation 
Assay (µMCA) targets different customers with the same goal: testing the patient-specific 
coagulation ability of blood samples. The customers for this product are hospitals, clinics, and 
pharmaceutical companies. The stakeholders are Doctors, Nurses, Physician’s Assistants, 
Patients, and Researchers.  
3.2.1 Customer Requirements 
Considering the needs and requirements of the customers and stakeholders in the device 
is critical to the design process. Table 3.1 displays the requirements for the customers and 
stakeholders. Customer requirements are discovered by analyzing the voice of the customer 
(VOC) and the voice of the market (VOM). The requirements are displayed with their relative 
importance to the customer. These requirements served as a basis for design of the final product. 
Customer Requirements Product Requirements Type Weight (%) 
Ease Safety Simplicity of Use FTS 15% 
High Throughput Fast Turnaround NUD 40% 
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Multiple Simultaneous Tests 
Accuracy Reproducibility FTS 35% 
Cost Include all materials on Chip NUD 15% 
 Table 3.1 Customer requirements for the Microfluidic Multi-Surface Coagulation Assay along with the 
corresponding product requirements are shown. The type and weight indicate the importance of the 
requirement in the scope of the product. 
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3.2.2 Critical-to-Quality Variables 
 The customer and stakeholder requirements need to be translated into characteristics of 
the end product. Critical-to-Quality Variables are the technical requirements that need to be 
incorporated in the end device from the Customer Requirements.  
Customer/Product 
Requirements 
Technical Requirement (CTQ) Deliverable 
Safety No dangerous chemicals or process steps 
Microfluidic Device 
Robotic Liquid Handler 
Minimum process steps 
Ease of use Microfluidic Device 
Robotic Liquid Handler 
Diffusive Mixing 
In-Unit liquid handling 
Fast Reading Times Microfluidic Device 
Robotic Liquid Handler  
~ 5 Minutes Process 
Time + 5 Minutes User 
Time 
Relevant Data Microfluidic Device 
Diffusive Mixing  
Multiple Clotting Surfaces 
Surfaces that trigger 
common clotting 
pathways  
Cost Effective Low material costs 
No dangerous chemicals or process steps 
Microfluidic Device 
Robotic Liquid Handler 
Diffusive Mixing 
Multiple Clotting Surfaces 
 
Multiple Simultaneous Tests Microfluidic Device 
Multiple clotting surfaces 
4 surfaces on Chip 
 
 
3.3 Competition 
3.3.1 Standard Tests- aPTT and PT 
 For many years two tests have been the benchmark of coagulation testing. These tests 
measure activated partial thromboplastin time (aPTT) or the prothrombin time (PT). The 
standard test for aPTT does not measure coagulation under flow but measures the time to 
coagulation of citrated blood in a test tube when calcium and a coagulation activator are added. 
Table 3.2 Customer and product requirements for the Microfluidic Multi-Surface Coagulation Assay 
are shown along with the technical requirements and deliverables that will help the product meet these 
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The time measured is the time it takes until a clot is formed and is a test of the ability to clot 
through the intrinsic pathway. PT measures the ability of blood to clot through the extrinsic 
pathway in a test tube. The test for PT requires that the blood plasma be incubated at 37oC 
before calcium is added in order to overcome the anticoagulant mixed with the blood. The test 
is performed with the addition of tissue factor to help observe the time to clot formation for the 
blood.  
 The combination of data from these tests offers an understanding of the clotting ability 
along both the intrinsic and extrinsic pathways. It is important to note that both of these tests do 
not occur under flow, meaning the data is extrapolated to understand how it occurs in the body 
where blood is constantly under flow. It is also important to note that the time the test takes is 
inconsistent due individual clotting ability of each blood sample.  
3.3.2 Devices (Siemens PFA-100, Haemonetics TEG 5000, VerifyNow Aspirin) 
 The current market contains other devices that test for similar factors as the Microfluidic 
Multi-Surface Coagulation Assay. Table 3.3 provides a summary of the competition including 
prices and characteristics concerning their functionality. In designing the Microfluidic Multi-
Surface Coagulation Assay it was important to assess similarities and differences between our 
device and the competition to provide significant improvement in design and data while 
observing the prices that the market is able to handle.  
Siemens PFA-100 
 The current competition in testing blood coagulation under flow is the Siemens PFA-100 
System. The PFA-100 system measures platelet dysfunction under high shear stress flow (shear 
rates of 4,000-5,000/s). It also is able to test for platelet adhesion and aggregation. The system 
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can either test blood across a collagen and ADP membrane or a collagen and epinephrine 
membrane. These tests require 800 µL of citrated blood and report the closure time for the clot 
formation in 5-8 minutes. The product function and market is the assessment of inherited, 
acquired, or drug-induced platelet dysfunction. The estimated price for the PFA-100 unit is 
about $30,000 with the cartridge price range between $30-50. Both the unit and cartridges are 
priced on a per contract basis when sold to a hospital or a lab8. 
AccuMetrics VerifyNow Aspirin 
 The AccuMetrics VerifyNow Aspirin is a point of care or laboratory device that delivers 
a qualitative test for the detection of platelet dysfunction. Though the device works for patients 
on an aspirin regimen it is not meant to diagnose the platelet dysfunction of patients with 
underlying platelet abnormalities or patients on a non-aspirin regimen. The system delivers data 
in 5 minutes about how well the blood clots when the patient is on an aspirin regimen by using 
an agonist to trigger the clotting pathway. The system uses an optical detection mechanism to 
measure the blood's reactivity to aspirin in the system. The unit itself costs $10,500 while the 
cartridges are offered sold in packs of 25 for $800. Like the Siemens PFA-100, there is a 
negotiated contract price established between the customer and the company when sold9. 
Haemonetics TEG 5000 
 The Haemonetics TEG 5000 Thrombelastograph Hemostasis Analyzer System is a 
diagnostic instrument that assesses bleeding and thrombotic risks and monitors antithrombotic 
therapies. Haemonetics also offers a PlateletMapping Assay that relates the potential response 
to antiplatelet therapy relative to the patient’s overall hemostasis. The TEG 5000 offers many 
different tests via their reagent kits. The processing unit is able to test two samples 
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independently of each other. Similar to the other two devices, the costs for the devices and 
materials are negotiable via contract. The estimated cost for a device is between $15,000 and 
$25,000 while the different materials are variable depending on the test being performed10. 
Conclusions 
 After comparing the Microfluidic Multi-Surface Coagulation Assay to the three main 
competitors on the market and the standard tests performed, the analysis shows the Microfluidic 
Multi-Surface Coagulation Assay (µMCA) is a better product. The functionality and costs of 
device versus its competition are shown in Table 3.3 below. All of the products deliver 
information about the ability of a patient’s blood to coagulate via activation. However the 
µMCA is the only device that can test both the intrinsic and extrinsic pathways under flow 
simultaneously thanks to the four-surface design. The µMCA offers the combined data of the 
competition at approximately the same cost. Like the competitive device, it has a fast 
turnaround time from start to end of the machine; however, as it does not require incubation 
time, the overall time is shorter. The preparation time for the µMCA is short since the addition 
of blood to the cartridge and placement of the cartridge into the processing unit are the only 
preparation steps. The benefits of the Microfluidic Multi-Surface Coagulation Assay are 
discussed in the following section. The µMCA is able to offer higher functionality at industry 
standard costs, making the tradeoff between functionality and cost nonexistent.  
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Competitor Prices Functionality 
Siemens PFA 100 ~$30,000/unit ~$30-50/Cartridge 
- Measures dysfunctional platelets 
under high shear stress. 
- Flows across collagen/epinephrine 
or collagen/ADP. But only one at a 
time. 
AccuMetrics VerifyNow 
Aspirin 
$10,500/Unit 
$32/Cartridge 
(Sold as: $800/25) 
- Measures platelet reaction with 
aspirin in a cell 
- Qualitative test for Platelet 
Dysfunction 
Haemonetics TEG 5000 
Thrombelastograph 
hemostasis Analyzer 
System 
$15,000-$25,000/Unit 
Various costs for cups, 
pipettes, and reagents 
- Assesses bleeding and thrombotic 
risks, and monitors antithrombotic 
therapies 
- Requires Preparatory activity 
Microfluidic Multi-Surface 
Coagulation Assay 
$30,000/Unit 
$100/Cartridge (Full 
Price) 
$30/Cartridge 
(Discount/Rebate Price) 
- Measures the clotting of blood on 
both the Intrinsic and Extrinsic 
pathway by flowing blood across 
four surfaces 
- 5 minutes read time 
- Minimal setup 
- Qualitative data 
 
 
3.4 Advantages of the Microfluidic Multi-Surface Coagulation Assay 
  Distinguishing features of the µMCA for determining patient specific blood 
characteristics make it more efficient to analyze patient coagulation abilities and provide more 
diverse results. The test is consistently faster than all devices currently on the market. For 
example, the most similar predecessor is the Siemens PFA-100 System, which gives results in 
5-8 minutes, indicating a relatively large range of times until data is produced. The Microfluidic 
Multi-Surface Coagulation Assay is able to produce data quicker and in a more consistent 5 
Table 3.3 A summary table of the main competitors of the Microfluidic Multi-Surface Coagulation 
Assay along with a description of their prices and functions 
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minutes due to the increase in rate of fibrin accumulation due to the kaolin-lipid-collagen 
surface (Chapter 5). Additionally, the Siemens PFA-100 System is only capable of measuring 
for one feature at a time-- Collagen/Epinephrine or Collagen/ADP16. The Microfluidic Multi-
Surface Coagulation Assay allows simultaneous measurement of both the intrinsic and extrinsic 
coagulation pathways by flowing blood over 4 surfaces at once. 
  Another significant advantage of the Microfluidic Multi-Surface Coagulation Assay is 
its ability to test blood coagulation under flow at arterial shear rates (200s-1), mimicking in vivo 
flow conditions and making the results of the test more physically relevant. Other common 
coagulation tests are the aPTT or the PTT, both of which test coagulation in a tube rather than 
under flow. In summary, the Microfluidic Multi-Surface Coagulation Assay tests coagulation 
more quickly, in physically relevant flow regimes, and through both pathways of coagulation. 
3.5 House of Quality 
The House of Quality (HOQ) relates customer and overall product requirements to one 
another. Its purpose is to focus on different aspects of the product development process and can 
be created at different stages in the process. For our product, the HOQ is specifically for the 
concept-stage of product design. The HOQ consists of six sections. The first section is 
associated with customer requirements and the second is associated with the quantitative and 
measurable technical requirements that correspond to at least one of the customer requirements. 
The third section is a correlation matrix that reveals the relationship between the customer and 
technical requirements that can be represented either qualitatively or quantitatively and used it 
indicate whether or not a technical requirement directly corresponds to a customer requirement. 
The ‘roof’ of the HOQ is a technical correlation matrix that shows the synergies and the 
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conflicts between the technical requirements. Synergies represent technical requirements that 
change in the same direction and are denoted by plus signs, conflicts between requirements that 
change in the opposite direction are represented by a minus sign and for unrelated variables, no 
sign is shown. The fifth section shows the weighing factors for the customer requirements, 
which have been previously determined in the customer requirements table. The final section 
gives the capabilities of the competitors in fulfilling the customer requirements, but is not 
usually included12. The HOQ for the Microfluidic Multi-Surface Coagulation Assay is shown in 
Figure 3.1. 
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3.6 Market Projection 
The revenue of the Microfluidic Multi-Surface Coagulation Assay will be derived from 
the initial markets of clinical trials and point-of-care applications. Though there are many 
possible markets in the future, only these markets will be considered for the purpose of our 
analysis. After initial product development, it is assumed that the µMCA will be manufactured 
for 13 years. The global coagulation-testing market is projected to increase at an 8.4 percent 
annual compound growth rate with the United States projected to make up 43 percent of the 
market in 2015, so it is assumed that our target markets will grow with the overall market10.  
After time spent developing the product and following the protocol for FDA approval, 
the µMCA is projected to reach 10% market penetration by the end of its first year of 
manufacturing. Since the market is so large, market share projection of the first year of 
manufacturing is 500,000 units or 5 percent market share. This is expected to increase to 
750,000 devices sold in the second year of production and then increase to 10% market share at 
1 million devices per year in the third year of production. Our estimate is that the Microfluidic 
Multi-Surface Coagulation Assay will maintain this market share for the remainder of its 
production years based on the vast size of the market and the relatively simple manufacturing 
process. According to our current manufacturing assumptions of 330 days of production per 
year and an 8 hour work day, the number of chips produced per day starts at 1,515 in the first 
year and increases to 2,275 in the second and 3,030 in the third year. The estimate also assumes 
that the processing unit has a life of 10 years and every institution will purchase a single device 
and some additional revenue will be generated from sales and repair of the processing unit. 
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We believe that the Microfluidic Multi-Surface Coagulation Assay provides a significant 
improvement to any existing technology to achieve the same result and is both faster and more 
versatile than its competitors in the market. Microfluidic lab-on-a-chip devices are becoming 
more commonplace in the healthcare industry and the Microfluidic Multi-Surface Coagulation 
Assay has the potential to secure its place among what is quickly becoming the new standard of 
processing devices.  
3.7 Patents 
The intellectual property of the Microfluidic Multi-Surface Coagulation Assay will be 
limited primarily by two patents. The first is US20130065260 A1 which discusses a method for 
a simultaneous assay of thrombin and plasmin generation filed on November 5, 201013. The 
second is held by Siemens Healthcare Diagnostics, US20070254324 A1 filed on April 12, 2007, 
which details methods for determination of platelet function under flow conditions14. However, 
neither should pose major obstacles to the Microfluidic Multi-Surface Coagulation Assay 
because we will file new patents with novel designs of the microfluidic chip and cartridge with 
four separate surfaces that is not at all covered in the two patents mentioned.  
3.8 Superior Product Concept 
The Microfluidic Multi-Surface Coagulation Assay has many features that give it an 
advantage over other competing products. The primary advantage is the fact that the µMCA can 
test the clotting of a single sample on four distinct clotting surfaces at once. After the double 
bifurcation, the blood sample flows down four separate channels and channel one is sheathed 
with calcium buffer and then flows over a different clotting surface. This advantage is important 
since it saves the physician or hospital both time and money because the patient’s response to 
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both intrinsic and extrinsic clotting pathways (and addition clotting surfaces in the future) can 
be determined. If a doctor or physician only needs to wait for one test, it is advantageous for the 
hospital because patients can be diagnosed and treated in a faster timeframe. The µMCA will 
allow hospitals to see a larger number of patients which in turn will allow the hospital to 
increase revenue. Furthermore, insurance companies and patients will also save money by 
having to pay for only a single test. Compared to its leading competitors, the µMCA reduces the 
need for guess-and-check procedures instead of deciding between multiple coagulation tests.  
Additionally, the time it takes for the µMCA to analyze a single sample is shorter than 
that of our competitors. Physicians can obtain more information from this one test in a shorter 
time than from any of our competitors. Additionally, many competitors do not test clotting 
under flow, which provides a more relevant simulation of what occurs in the human body and 
thus will give the doctor more accurate and applicable data. Our product also has the capability 
for customization and further development. The lengths of the channels are 4 cm, but clotting 
surfaces can be deposited anywhere along this channel. Further development of the µMCA 
could be done to include different surfaces or reagents or different diffusion lengths. 
3.9 Other Important Considerations 
Other concerns with regards to product design include safety and environmental 
concerns, especially when working with biological products that will be used for human 
diagnostics. The manufacturing facility must also be safe for the employees that operate the 
machines. Material Safety Data Sheets (MSDS) for all reagents used in our manufacturing 
products are referenced in Appendix 13.1 and are available upon request. None of the reagents 
used cause any significant environmental concerns.  
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3.10 Summary 
Our market analysis has shown that the µMCA is an innovative new product that 
satisfies unmet need in the market for blood testing and diagnostics for a reliable technology to 
test for clotting on multiple surfaces under sheath flow. When it comes to blood coagulation 
measurement, speed and accuracy are essential and there will always be a need for a faster and 
more reliable testing method. Through the use of microfluidic technology, the µMCA can fulfill 
this need and has the ability to surpass all of its competitors on the market. Since microfluidic 
devices have been introduced to the market already, the Microfluidic Multi-Surface Coagulation 
Assay can highlight its advantages over existing products. We project that we will achieve sales 
of 1 million cartridges per year at around 10 percent market penetration, and we will receive 
some additional revenue from the sale of the processing unit and service contracts and fees.  
 According to our business model, initially we will target clinical trials and point-of-care 
markets for the µMCA. We will target pharmaceutical companies, biotechnology companies 
who both develop drugs and run clinical trials as well as hospitals, and clinical laboratories who 
administer point-of-care treatments. We also plan to expand to additional research and 
diagnostic applications in the future.  
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Chapter 4: Blood Chemistry 
4.1 Introduction 
 Blood serves many functions in the body including oxygen and carbon dioxide transport 
as well as the transportation of waste products away from cells. One more specialized function 
which is relevant here is the formation of a blood clot. This process involves a complex series of 
reactions which is still under study today. 
4.2 Coagulation Cascade 
 The coagulation cascade is a series of reactions that occur in the blood during a clotting 
event. There are two pathways to coagulation, the intrinsic pathway or the extrinsic, or tissue 
factor, pathway. The Intrinsic Pathway is initiated by exposure of blood to a charged surface or 
collagen. The Extrinsic Pathway is initiated when blood comes in contact with tissue factor. 
Figure 4.1 illustrates the basic reactions that proceed from an initiation event, from activated 
platelets to stabilized fibrin. 
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Figure 4.1 Diagram of the coagulation cascade. Both the intrinsic and extrinsic pathways are shown. Each Roman 
Numeral denotes a protein in the cascade, and proteins above an arrow indicate promoters of a reaction. Blue 
arrows highlight calcium dependent steps. Platelets are in green and stabilized fibrin is in red, indicating the colors 
of light under which they will fluoresce in the device. 
 Every protein in Figure 4.1 promotes reactions downstream of its creation. There is 
additionally a vast degree of positive feedback within the cascade. For example, thrombin 
promotes the conversion of Factor XI to XIa, VIII to VIIIa, V to Va, XIII to XIIIa, in addition 
to the downstream conversion of fibrinogen to fibrin. Once later stages of the cascade have 
progressed, clot accumulation rapidly increases. The Microfluidic Multi-Surface Coagulation 
Assay is designed to monitor patient specific coagulation abilities and directly measures both 
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platelets and fibrin accumulation on a clot-promoting surface. Typical clotting times range from 
6-8 minutes, but the kaolin surface on the chip allows a faster clotting time by taking full 
advantage of the Intrinsic Pathway. 
4.3 Coagulation and the Microfluidic Multi-Surface Coagulation Assay 
 An important feature of the coagulation cascade is the calcium dependence of several 
steps. Without calcium, these reactions cannot occur and a clot will not form. This can be taken 
advantage of by using a chelator to inhibit clotting when blood is drawn from a patient. 
Chelation of blood binds all free calcium, zinc, and magnesium ions in the blood. The blood 
used for the Microfluidic Multi-Surface Coagulation Assay will be chelated using trisodium 
citrate, as is standard practice in clinical and hospital settings and thus does not require the 
additional purchase of specialty coagulation inhibitors. To recalcify the blood and allow clotting 
to progress, blood will be sheathed with a calcium buffer. The fluids on the chip are in the 
laminar flow regime and as a consequence distinct layers of flow will remain and blood will 
remain independent of the recalcification buffer. However, small mobile calcium ions will be 
transported by diffusion and convection as discussed in Chapter 5 and the blood will be 
recalcified. 
 To measure the extent of clotting, fluorescent markers for platelets and fibrin will be 
mixed into the blood. As these proteins accumulate on the device surfaces, fluorescence levels 
will increase. These levels will be analyzed and compared with typical values for blood, and 
thus a patient's clotting abilities can be determined. 
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Chapter 5: The Microfluidic Multi-Surface Coagulation Assay Chip  
5.1 Overview – Lab-on-a-Chip Microfluidic Devices 
Lab-on-a-chip technology employs microfluidic technology in order to generate a device 
that integrates one or more laboratory functions into a chip whose size is on the order of square 
centimeters. The study of microfluidics is the study of the behavior, flow and precise control of 
fluids that flow through channels or other areas that are on the micro-scale or smaller. The 
growing field of lab-on-a-chip microfluidic technology aims to improve on and extend the 
potential of bioassays as it enables small-scale fluid control and analysis2. When compared to 
more traditional methods of collecting blood samples and sending them to the hospital 
laboratory for analysis that could take hours or days, lab-on-a-chip presents an attractive 
alternative that is faster, cheaper, and much less labor-intense. Other advantages of the lab-on-a-
chip approach to medical devices go beyond the ease of testing and the convenience of 
receiving immediate results in the field. The sensitivity of the chip means that the sample size 
required is much smaller. The microfluidic platforms are also capable of containing a well-
defined set of fluidic unit operations such as fluid transport, separation and mixing as well as 
providing a low-cost product for manufacturer fabrication18. 
The technology of creating fast and efficient micro-scale devices has many appealing 
applications. Among them include the analysis of enzyme activity and kinetics, testing of drug-
protein interactions, protein expression, DNA synthesis, and membrane protein studies2. 
Outside of the medical field, microfluidic platforms have been studied for fields such as 
environmental monitoring of pollutants and even in basic scientific research to increase the 
speed of conventionally tedious and time-consuming tests18.  
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5.1.1 Chip Diagram 
  
 
 
 
 
 
 
 
  
  
 
 
 
The 3-D model of our device is shown in Figure 5.1, above. The Microfluidic Multi-
Surface Coagulation Assay contains two components, the cartridge and the chip. In the coming 
sections of this chapter, the design of each component is explored. The principal of the design is 
that the doctor only needs to add 1 mL of the citrated blood sample to the cartridge before 
insertion into the processing unit. The device is one-use and disposable and will be sold already 
loaded with the reagents, clotting surfaces, and pipette tips necessary to conduct the test. After 
Figure 5.1 3-D model of the Microfluidic Multi-Surface Coagulation Assay device created using Google 
SketchUp. The cartridge and chip are both pictured with the walls of the chip and cartridge set to 
transparent so the microfluidic device and pipettes are visible. The red represents citrated blood, blue the 
dye, green the calcium buffer, and yellow the clotting surfaces. 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
34 
 
depositing the sample into the device, the doctor then places the device into an analytical 
processing unit that contains the software and mechanical capabilities to automatically conduct 
the test. An overhead view of the device can be seen in Figure 5.2 with colors to indicate the 
various reagents on the device.  
 
 
 
 
 
 
 
 
 
 
  
 
5.1.2 Process Flow Sheet 
 The Microfluidic Multi-Surface Coagulation Assay Chip will take less than ten minutes 
from blood draw to production of results. These ten minutes are outlined in detail in Figure 5.2. 
The blue steps are actions required by the physician: blood draw, transfer of 1 mL of citrated 
blood onto the chip, insertion into the machine, and (roughly 6.5 minutes later), disposal of the 
Figure 5.2 An overhead view of the 3-
D model of the Microfluidic Multi-
Surface Coagulation Assay device 
created using Google SketchUp. The 
red represents citrated blood, blue the 
dye, green the calcium buffer, and 
yellow the clotting surfaces. The 
dimensions of the chip are also shown. 
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chip in the biohazard bin. Red steps denote liquid handler steps, including pipetting and 
translational motion of pipettes within the machine. The green bars denote the ‘read’ steps, at 
which time the machine simultaneously draws blood through the device and reads fluorescence 
over time.
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5.1.3 Diagrams of Process on Cartridge within Processing Unit 
 To gain a full understanding of the Microfluidic Multi-Surface Coagulation Assay, the 
mechanics of how it analyzes blood clotting must be understood. Table 5.1 and Figure 5.1 show 
a step-by-step process of what occurs on the device from the deposition of the blood sample to 
when it is inserted into the processing unit until the results are completed. 
Color Material 
Blue Dye 
Green Ca2+ Buffer 
Dark Grey Empty Wells 
Grey Pipette Tip 
Red Blood 
Purple Blood + Dye Mix 
Orange Ca2+ Buffer + Blood + Dye 
Yellow Clotting 
 
 
 
Figure 5.4a: Image of the cartridge right out of the Package 
Table 5.1: Key for the following Diagrams of the Process on the Chip 
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Figure 5.4b: Step 1: Add Blood to the Cartridge 
 
Figure 5.4c: Once in the Processing Unit the Liquid Handler picks up a pipette tip and mixes dye with the blood 
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Figure 5.4d: The Liquid Handler then draws some Dye+Blood Mix and adds it to the blood well on the chip 
 
Figure 5.4e: The Liquid Handler then ejects the first tip, picks up the second. It then picks up buffer from the 
reservoir and adds it to the 8 smaller wells. 
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Figure 5.4f: As the Liquid Handler ejects the pipette tip in its original location; the syringe pump begins pulling, 
starting flow  
 
Figure 5.4g: As the liquid starts to flow, the Ca2+ diffuses into the Blood+Dye Mix  
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Figure 5.4h: As the calcified blood flows over the surfaces clots begin form  
 
Figure 5.4i: Image of chip after process is finished. Cartridge is ejected and disposed of in a Sharps bin. 
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5.1.4 Flow through the Microfluidic Chip 
 After the citrated blood sample is injected into the cartridge and the device has been 
inserted into the processing unit, the blood sample is mixed with the dye and deposited onto the 
microfluidic chip portion of the device. Since we are testing blood clotting on multiple surfaces, 
the flow channel must be divided. Though our goal is only to test three surfaces, dividing the 
channel into three is much more difficult than dividing the channel into four by bifurcation, so it 
was decided that we will have four channels and test one of our existing surfaces twice and the 
fourth surface will be available for future testing on the device. Figure 5.5 shows the double 
bifurcation that occurs before the calcium buffer is added. 
 
 
 
 
 
 
 The calcium buffer is added to two wells on either side of the four channels, making a 
total of eight calcium wells. Once the bifurcation is complete, the blood and calcium flow down 
the channel with calcium buffer forming a sheath around the blood and the Ca2+ diffusing into 
the blood causing recalcification, which will be modeled and examined later in this chapter. 
Initially, different microfluidic mixing was considered such as the herring-bone mixer and the 
serpentine mixer, but it was decided that diffusion would be the most simple and reliable 
Figure 5.5 Bifurcation of the citrated blood sample. Inside the device, the blood 
sample is divided into four microfluidic channel, each with a different clotting surface.  
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method of on-chip recalcification. The blood and buffer flow through the channel and over the 
clotting surface where cameras capture images of the blood as platelets and fibrin form. Finally, 
the blood and buffer mixture flows into the waste reservoir and the entire device is discarded 
after the test is complete. 
5.1.5 SolidWorks Model for Testing 
 The optimal design of the microfluidic platform was explored by creating several 
different geometries and testing them in the lab in order to determine which satisfied the 
necessary recalcification requirements. The 2-D CAD software SolidWorks was used to create 
four different designs for the channel, as shown in Figure 5.6.  
 
 
 
 
 
 
 
 
 
 Figure 5.6. A SolidWorks design of the channels used in laboratory testing of the Microfluidic Multi-Surface 
Coagulation Assay. Angles vary from left to right from 20⁰ to 30⁰ to 45⁰ to finally 60⁰. 
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Each channel is 4 cm in length in order to allow the clotting surface to be deposited along 
several locations down the channel to determine what length is most optimal. Four different 
angles were tested: 20⁰, 30⁰, 45⁰, and 60⁰. A closer view of the four angles can be seen in 
Figure 5.7. The experimental process of determining the optimal design is detailed in the 
subsequent sections.  
 
 
 
 
 
 
 
5.1.6 Process Conditions and Reagent Volume 
 The µMCA Chip should be stored at -80°C until use to preserve the biological 
components of the chip such as antibodies and tissue factor. While the HEPES Buffered Saline 
based calcium buffer does not need to remain frozen to preserve functionality, for convenience 
the entire chip can be frozen at -80°C. 1 mL of citrated whole blood should be added to the chip 
right before placement in the machine. The process itself will occur at room temperature, and 
thus the chip should be allowed to reach room temperature just prior to use (20-30 minutes).
  
 
Figure 5.7 A close up of the four angles for the microfluidic diffusive mixing that were 
manufactured and tested in the laboratory.  
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
45 
 
5.2 On-Chip Recalcification 
 To overcome the effects of chelation, blood will come into contact with a calcium buffer 
sheath and calcium will diffuse into the blood and allow clotting to progress. To determine how 
long the blood needs to be in contact with calcium to achieve a centerline concentration of 
10mM in calcium ions, three methods were used. An analytical solution to the transient mass 
transfer equation was the first and most basic method used to give an approximate length for 
diffusion.  Following this solution, the flow through the chip was modeled using COMSOL.  
Afterwards, the chip was tested in the lab to confirm our predictions. 
5.2.1 Transient Diffusion in a Semi-Infinite Plane Sheet 
 The flow regime was modeled as a semi-infinite plane sheet, and thus diffusion in the x 
direction as a function of time was determined. By the time flow is well developed within the 
channels, concentration of calcium along the y axis, or at a point along the flow channel, can be 
determined using average velocity and the value of concentration at a given time. Equation 5.1 
along with boundary and initial conditions in equations 5.2-4 specify the transient one 
dimensional mass transfer problem. Figure 5.8 provides a simplified diagram of the problem. 
         𝜕
2𝐶
𝜕𝑥2
= 1
𝐷
𝜕𝐶
𝜕𝑡
          5.1 
       𝑐(𝑡 = 0, 𝑥) = 0      5.2 
       𝑐(𝑡, 𝑥 = 1) = 𝑐1      5.3 
        
𝜕𝑐
𝜕𝑥
�
𝑥=0
= 0             5.4 
 
where D= diffusivity of calcium in blood= 1.25*10-9 m2/sec 
 C= concentration of calcium in the blood, mol/L 
 x= distance from the center of the channel, m 
y= distance from mixing point in the channel, m 
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Figure 5.8 Diagram of boundary conditions applied to solve Equation 1. Blood flow region is depicted in red and 
the buffer flow region is depicted in yellow. Half of the flow regions are shown, as conditions are symmetric within 
the channel. The concentration of calcium in the blood at t=0 is defined as 0, and the concentration in the buffer is 
defined as a constant, co. The x axis increases along the bottom of the figure. Figure not drawn to scale. 
To solve, it was assumed that the rate of diffusion from the right was equal to the rate of 
diffusion from the left. Additionally, diffusion was neglected in the y and z direction. The 
solution takes the form of the error function: 
 𝑐(𝑡)−𝑐𝑜
𝑐1−𝑐𝑜
= ∑ (−1)𝑛𝑒𝑟𝑓𝑐 �(2𝑛+1)ℓ−𝑥
2√𝐷𝑡
�∞𝑛=0 + ∑ (−1)𝑛𝑒𝑟𝑓𝑐 �(2𝑛+1)ℓ+𝑥2√𝐷𝑡 �∞𝑛=0      5.5 
c(t)= concentration at point x in the plane sheet 
c1= concentration at x=l 
co= concentration in the plane sheet/ buffer 
l= half width of blood flow 
x= location along the x axis 
t= time (sec) 
 
The result stems from the significant assumption that concentration in the buffer and thus at the 
interface remains constant. To mimic these results in the laboratory, a higher concentration of 
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calcium in the buffer can be used. The results are collected and graphed in Crank's The 
Mathematics of Diffusion18, and reproduced here: 
 
Figure 5.9 Concentration over time in a sheet with a constant source at x=l. Lines are plotted on values of Dt/l2, 
and variables are defined in Equation 5.2. (Crank) 
Using Figure 5.9, and assuming a buffer concentration of 20mM in calcium, it was determined 
that it would take 4.75 seconds to achieve a concentration of 10mM in calcium at x=0. Using a 
superficial velocity of 0.4 cm/sec, this equates to 1.94 centimeters of flow. 
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5.2.2 COMSOL 
 Introduction to COMSOL 
COMSOL Multiphysics® is a finite element, solver, and simulation software that can be 
used to model and calculate different situations within a given model. The software offers many 
different modules that can be used individually or in a coupled system. To model the 
Microfluidic Multi-Surface Coagulation Assay a model of the mixing channel was imported 
from SolidWorks®. The microfluidic channel was modeled in 2D on SolidWorks® for different 
lengths of the channel in which sheath flow occurs. Design of the SolidWorks® model is 
discussed Chapter 6. Some of the different physics modules offered include a laminar flow 
model and a dilute species diffusion model. A combination of these models and the flow path 
from SolidWorks® were used to estimate characteristics of the model23. 
Design Strategy using COMSOL 
 The objective of using the COMSOL simulation was to simulate the mixing of the 
streams using parameters found in the analytic solution before the prototype was built. We were 
testing to find the optimal angle of mixing and concentration of buffer to use to compare to the 
prototype tests.  
  The analytical solutions were used as a basis for some of the parameters used in the 
model. A list of the parameters used for the study is located in Table 5.2. The COMSOL 
simulation studies the mixing of the flows without the analytical assumption of infinite 
concentration in the sheath flow. We however still ignore the z-axis under the two-dimensional 
fluid flow assumption. Using the shear rate found in the analytical solution a flow rate was 
determined which was set as the goal exit velocity for the cross sectional area of the device. The 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
49 
 
estimated pressure drop we expected to use with the syringe pump was 200 Pa (1.5 mmHg). The 
Ca2+ buffer concentration was found by running various concentrations on COMSOL at the 30° 
mixing angle. The chosen buffer concentration 40 mM. It is a slight overestimation because we 
are looking to minimize costs by using the lowest concentration necessary while still bringing 
the centerline concentration to the required amount. Due to limitations in COMSOL in 
characterizing multiple fluids in the system, the viscosity and density of the both fluids were 
estimated as that of blood. The last parameter was the length of the flow channel. The original 
simulations were performed across the entire length of a 4.4 cm channel designed for lab testing 
different surface locations along the flow channel. As the velocity was set at the exit, we 
performed a second study for a shorter flow channel (2cm). This study was conducted using the 
COMSOL optimal mixing angle of 30⁰ and concentration of 40mM.  
Parameter Value Units 
Density 1.06 g/ml 
Viscosity 3 cP 
Ca2+ Concentration 40 mM 
Mixing Angles 20, 30, 45, 60 Degrees 
Target Flow Rate 8.09 x 10-5 mL/s 
Target Velocity 4.087 mm/s 
Target Shear Rate 200 s-1 
Estimated Pressure Drop (Pa) 200 Pa 
Estimated Pressure Drop (mmHg) 1.5 mmHg 
Flow Channel Length 2, 4.4 cm 
 
 
The centerline concentration for each of the models was found by creating an array of 
points along the centerline and a concentration variable (Figure 5.10b). Once the study was 
performed a plot graph was created showing the concentration at each of the points at its 
location along the flow channel. Initial data gathering was a problem as the data showed errors 
Table 5.2 The parameters for building a model to test recalcification on COMSOL are 
shown. 
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due to the quality of the mesh COMSOL was using as the mathematical basis for calculations. 
The data presented was all studied under the “Finer” COMSOL mesh setting.  
Results from COMSOL 
 The studies observing the different angles were all tested at a buffer concentration of 40 
mM. It was discovered that both the 45° and 60° mixing angles the buffer diffused extremely 
fast and as such caused a quick step up in concentration and continued along the flow channel at 
that equilibrium concentration. This is most likely caused by the angle of incidence for the 
larger two angles forcing the buffer stream into the blood, creating wider buffer paths (Figures 
5.12 and 5.13). This is not ideal for use because it narrows the blood clotting area on the 
surface. The ideal mixing creates a sheath and allows the calcium to gently diffuse into the 
blood (Figures 5.11). The angle of incidence did not allow for as much mixing along the 
channel for the 20° mixing angle. Thus 30° was found to be the optimal angle according to these 
COMSOL simulations. 
Angle (degrees) Center Line Concentration Distance to 10mM Center Line Concentration 
20 8.5 mM Does Not Reach 
30 11 mM 16 mm 
45 26 mM Immediately Higher 
60 31 mM Immediately Higher 
 
  
The simulation testing the 2 cm flow channel showed that the correcting the length of 
the flow channel reduced the distance to the 10mM centerline concentration calculated in the 
analytical section. With the 30° mixing angle and 40mM Ca2+ buffer the centerline 
concentration reaches and stays at the required centerline concentration for a short amount of 
time. This was found to be optimal design studied on COMSOL. 
Table 5.3 Comparison of Center Line Concentrations at the Different Mixing Angles. 
Parameters: 40 mM Initial Concentration 
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a)  
b)  
Figure 5.10: a) Graphs of calcium concentration vs. position in micrometers for 30° mixing angle, 2cm 
Flow channel , and 40 mM inlet buffer concentration. b) COMSOL model of 30° mixing angle and 2 cm 
flow displaying collection data points along the y-axis. 
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Figure 5.11: COMSOL Simulation of mixing at 30° and 40mM Inlet Concentration 
 
 
Figure 5.12: COMSOL Simulation of mixing at 45° and 40mM Inlet Concentration 
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Figure 5.13: COMSOL Simulation of mixing at 60° and 40mM Inlet Concentration 
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5.2.3 Lab Tests and Results 
 The first test for on-chip recalcification was run using a fluorescent dye in the buffer in 
lieu of calcium, since it would be easiest to confirm functionality in preliminary experiments. 
The diffusivity of the fluorescent marker was slightly lower than that of calcium, so diffusion 
would most likely be understated. Additionally, the viscosity of the buffer was not adjusted to 
that of blood in this experiment, so for this experiment the viscosity of blood is 3 cP and the 
viscosity of the buffer is 1 cP. Figures 5.14a and 5.14b show the fluorescent intensity as a 
function of position along the channel. The earliest time points are in darker colored lines, and 
the latest time points are lighter. The images in Figure 5.14 are from studies using blood and 
buffer flow rates of 1.91 μL/sec. Both 20° and 60° angles of incidence between blood and buffer 
were tested. It is clear from Figure 5.14 that the fluorescent dye reaches a more even 
concentration over time with the smaller angle of incidence. 
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a.  
b.  
Figure 5.14 a) Fluorescent intensity versus position along the microfluidic channel width over time for a 60° angle 
of incidence between buffer and blood. b) Fluorescent intensity versus position along the microfluidic channel 
width over time for a 20° angle of incidence between buffer and blood. For both images, changes in position along 
the channel are shown by fading of the lines, ie., the smaller distances are shown darkest and the later times are the 
lightest in shading. 
 
 Figure 5.15 plots the percent of inlet concentration against the distance in millimeters 
along the channel for different ratios of blood to calcium buffer, with a constant blood flow rate 
of 1.91 μL/sec. The values for percent of inlet concentration were determined at the center of 
the channel using level of fluorescence. It is clear that as the ratio of blood to buffer decreases, 
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the center of the channel reaches a larger percent of the inlet concentration in a shorter distance-
- i.e., a shorter time. Since in the Microfluidic Multi-Surface Coagulation Assay chip, calcium 
will replace the fluorescent marker, it is expected that in the next experiment centerline 
concentration will increase to the same levels in a shorter distance. 
 
Figure 5.15 Percent of inlet concentration of fluorescent marker at the center of the channel versus distance along 
the channel. Ratios denote the ratio between blood flow rate and fluorescent buffer flow rate, with a constant blood 
flow rate of 1.91 μL/min and at a 20° angle of incidence between the blood and the buffer. 
 
 The width of blood in the channel varied with the ratio of blood to buffer, and similar 
trends are see between this blood width and the ratio. As the width of blood in the channel 
decreases, the rate at which the centerline concentration as a percentage of the inlet buffer 
concentration changes goes down. This change is plotted in Figure 5.16, and both 20° (small) 
and 60° (large) angles of incidence are shown. 
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Figure 5.16 Percent of inlet concentration of fluorescent marker per length in millimeters versus width of blood in 
channels. As blood width in the channel decreases, the rate at which the fluorescent marker diffuses into the blood 
decreases. Channel width for all measurements is 300 μm. 
  
Instead of calcium in these preliminary experiments, fluorescein isothiocyanate (FITC) 
was mixed into the buffer and its fluorescence along the channel monitored at different lengths 
along the channel to determine efficacy of the design. Figure 5.17 displays the results, with each 
line representing a different length for diffusion of FITC. The times for the data points, 
determined from a flow rate of 4.09 mm/s, range from 0 through 10 seconds, in intervals of 
approximately 1.5 seconds. 
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Figure 5.17 Fluorescent intensity versus position along the microfluidic channel for different diffusion distances 
for the 45° angle of incidence between buffer and blood. 
 
 Figure 5.18(a) adjusts the diffusion of FITC to model and predict the diffusion of 
calcium within the Microfluidic Multi-Surface Coagulation Assay. The diffusion was adjusted 
for different values in 0 
diffusivity, since the diffusivity of calcium is much higher than that of FITC. Figure 5.18 (b) 
predicts the centerline concentration of calcium assuming a 30 mM calcium buffer. According 
to the model, the centerline concentration will reach the desired minimum of 10 mM in a 
distance of about 20 mm. The results are consistent with the analytical methods for contact 
length, with the adjustment of buffer concentration to more closely mimic a 'constant' 
concentration at the interface. 
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a.  b.  
Figure 5.18 (a) Centerline percent of inlet concentration of FITC or Ca2+ versus distance from the point of 
intersection between buffer and blood. (b) Prediction for centerline concentration of Ca2+ in mM versus distance 
along the channel, determined using a 30 mM calcium buffer for reference. 
 
 To determine the optimal length for which the blood should be in contact with the 
calcium buffer, another experiment was done. The buffer was mixed with methyl cellulose to 
increase the viscosity to that of blood (3 cP). Blood was flowed through the channels with an 
angle of intersection of 45°, and 8 different microfluidic devices were created with collagen 
strips placed at different distances from the point of intersection. Figure 5.19 a and b show the 
platelet and fibrin fluorescent intensity, respectively, over time in minutes for different calcium 
diffusion distances to collagen surfaces using a 30 mM calcium buffer. Figure 5.19 c and d 
show the platelet and fibrin fluorescent intensity, respectively, over time in minutes for for 
different diffustion distances to collagen surfaces using a 0 mM calcium buffer-- the control. 
While the response for the 30 mM buffer is highest for the 35.237 mm diffusion distance, it is 
not necessary to achieve this level of fluorescence or, in the case of the Microfluidic Multi-
Surface Coagulation Assay, calcium concentration. Based on our simulations and subsequent 
lab testing, our design uses a 2 cm diffusion distance between the point of intersection and the 
clotting surfaces. The control confirms that the clotting response is due to the calcium diffusing 
into the blood over the diffusing distance. 
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a.  
b.  
c.  
d.  
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Figure 5.19 (a) Platelet fluorescent intensity versus time of flow in minutes of blood over collagen surfaces at various lengths along microfluidic 
channels using 30 mM calcium buffer. (b) Fibrinogen fluorescent intensity versus time of flow in minutes of blood over collagen surfaces at 
various lengths along microfluidic channels using 30 mM calcium buffer. (c) Platelet fluorescent intensity versus time of flow in minutes of 
blood over collagen surfaces at various lengths along microfluidic channels using 0 mM calcium buffer. (d) Fibrinogen fluorescent intensity 
versus time of flow in minutes of blood over collagen surfaces at various lengths along microfluidic channels using 0 mM calcium buffer. 
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 Figure 5.20 plots the time in seconds for 25% of maximum fluorescent intensity (red and 
blue lines) and the calcium centerline concentration in mM prediction versus the distance from 
the point of intersection along the channel in millimeters. The minimum time to 25% max 
fluorescence is apparent around 35 mm along the channel. Again, the maximum level of 
fluorescence is not required in the actual device and the data for 20 mm along the channel is 
adequate for the Microfluidic Multi-Surface Coagulation Assay. 
 
Figure 5.20 Time to 25% of maximum fluorescent intensity in seconds (red and blue) and centerline Ca2+ 
concentration in mM (green) versus distance from the point of intersection in mm for platelets (blue), fibrinogen 
(red), and calcium prediction from Figure 5.14 (green). 
 
 Figure 5.21 displays an image from the computer in the lab showing side by side the 
fluorescence of fibrinogen and platelets on the collagen surface for 45° (left) and 20° (right) 
angles of incidence between blood and calcium buffer. The twenty degree angle of incidence 
provided a more vivid clotting event on the collagen surface, indicating better calcium diffusion 
which leads to a more fluorescent clot. 
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Figure 5.21 Platelet and fibrinogen accumulation on collagen surface for 45° (left) and 20° (right) angles of 
incidence between calcium buffer an citrated blood. It is clear that the 20° angle of incidence promotes better 
diffusion of calcium into blood as more fluorescence (clotting) is visible. 
 
 Figure 5.22 a displays an image of the intersection between the blood and the Ca2+ 
buffer for a 20° angle of intersection. Figure 5.22b shows the downstream clot on a collagen and 
tissue factor surface after 10 minutes of flow and 22.3 mm downstream from the intersection. 
High levels of fluorescently marked platelets and fibrinogen have accumulated on the clotting 
surface by this point, which would not have occured without the calcium buffer, as 
demonstrated in Figure 5.23. Figure 5.23 shows the control 0 mM calcium buffer on the left 
hand side with the 30 mM buffer on the right hand side. No significant clotting occured in the 
control, indicating that the cause of the platelets and fibrin accumulation on the clotting surface 
is due to the presence of calcium in the buffer. 
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a.  
b.  
Figure 5.22 a) Magnified image of intersection between citrated blood sample and calcium buffer at a 20° angle of 
incidence. b) Image of clotting surface (collagen and tissue factor) downstream of the intersection after ten minutes 
of flow. Clotting surface is placed 22.3 mm from the intersection. Since clotting occurs, calcium diffusion by 
sheath flow was a success. 
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Figure 5.23 Accumulation of platelets (red) and fibrinogen (green) after 11 minutes of flow over collagen clotting 
surface 22.3 mm downstream of the location of incidence between the calcium buffer and citrated blood with CTI, 
a Factor XII inhibitor. Blood was sheathed with a 0 mM (left) or a 30 mM (right) calcium buffer with a 20° angle 
of incidence between the streams. It is clear that the calcium is the source of the high platelet and fibrinogen levels 
on the right hand side,l since the 0mM Ca2+ control results in no coagulation on the collagen surface. 
 To further demonstrate the success of our model and its functionality, Figure 5.24 
provides a visualization of the diffusion within the buffer-sheathed blood. Instead of calcium, 
Texas Red Dye is mixed into the buffer in the sheath stream to allow observation of the 
diffusion in the channel. Snapshots of regions within the flow streams are shown at the point of 
intersection and at distances of 23.4 and 41.1 mm from this point of intersection. The result 
mimics that of the diffusion modeled in COMSOL and shown in Figures 5.11-13.  Based on our 
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experiments, we can say with confidence that this method for on-chip recalcification of citrated 
blood will work in the context of our device. 
 
 
Figure 5.24 Visualization of diffusion of Texas Red Dye into a stream of citrated whole blood with CTI. The 
diffusion of the red dye appears to follow similar patterns as seen in the COMSOL simulation, Figures 5.11-13. At 
a distance of 23.4 mm, dye appears to have reached the center of the stream. By a distance of 41.1 mm, dye 
concentration is high throughout the stream of blood. Since the diffusivity of this Texas Red Dye is lower than the 
calcium in the buffer, calcium diffusion is expected to occur more quickly within the channel.  
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5.3 Device Design 
When considering the design of the device, each component is first considered 
separately and then they are considered in the scope of the entire design. The focus of this 
section will be on the design of the cartridge and its components as well as the composition of 
the clotting surfaces. For the cartridge, the number of pipettes and the locations of the reagent 
reservoirs were considered with respect to how the device will operate inside the processing 
unit. For the chip, the optimal clotting surfaces are determined through experimentation. The 
exact design of the microfluidic chip that is inserted into the cartridge of the device will be 
detailed in Chapter 6.  
5.3.1 Chip Holder (Cartridge) 
 The cartridge is the plastic portion of the device that contains the pipette tips used by the 
processing unit and both the calcium buffer solution and the dye solution. It is also the place 
where the physician or technician will deposit the blood sample into the device in order to 
analyze it. Inside of the processing unit, a liquid handler mixes the blood with the dye and also 
deposits both the blood-dye mixture and the calcium buffer into the appropriate wells. Initially 
we began our design of the cartridge with the idea of having a robotic liquid handler that would 
only need to move in two directions. But this approach led to a cartridge that was too long with 
a lot of wasted space. The current design uses space the most efficiently, but requires the robotic 
liquid handler to move along all three directional axes. Besides providing the reagents and the 
pipette tips, the cartridge also offers structural support for the chip of the device and is where 
the physician or technician will primarily handle the device so as to prevent disturbance of the 
more sensitive microfluidic component.  
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5.3.2 Tips on Cartridge  
 The number of tips inside of the cartridge depends on the number of liquid handling 
steps involved with the analysis. The first liquid handling step involves mixing the blood with 
the dye and in the same motion, depositing the mixture onto the microfluidic chip. The second 
liquid handling step is the deposition of the calcium buffer into the wells surrounding the blood 
channels. Since only two liquid handling steps are required, it is possible to have a cartridge 
with only two pipette tips loaded. However, because pipette tips are relatively inexpensive, a 
total of four pipette tips are loaded into the device in case one of the liquid handling steps is not 
successfully completed.  
5.3.3 Fluorescent Antibody, Calcium Buffer 
 Within the 'dye' well will be a mixture of fluorescent antibodies that target platelets and 
fibrin. As platelets and fibrin accumulate on the clotting surface during flow, these antibodies 
will accumulate on the proteins. Light at the excitation wavelength of the respective fluorescent 
antibodies will be shone on the surfaces in quick succession. The level of fluorescence will be 
determined and the extent of platelet and fibrin accumulation on the surface will be measured, 
and finally the extent of coagulation can be determined. 
 The calcium buffer for recalcification will be 30 mM, allowing excess in calcium to 
increase its diffusion into the blood. The buffer itself will be mixed into HEPES-buffered saline, 
a mixture of sodium hydroxide, sodium phosphate dibasic dihydrate, HEPES, and ultrapure 
water. This can be purchased premixed from companies such as Sigma Aldrich, but is relatively 
simple and inexpensive to make from its components. 
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5.3.4 Diagram 
 Figure 5.25 shows the cartridge in relation to the chip of the device. The chip is mounted 
onto the cartridge during the manufacturing of the device.  
 
 
 
 
 
 
 
 
 
Figure 5.25 3D model of the mounting of the Microfluidic Multi-Surface 
Coagulation Assay onto the cartridge 
Figure 5.26 3-D model of the Microfluidic Multi-Surface Coagulation Assay cartridge created using Google 
SketchUp. A. The walls are transparent to allow a view of the pipette tips and the reservoirs extending into the 
cartridge. B. The cartridge as it would look to a consumer after the citrated blood has been added 
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 Figure 5.26 shows only the cartridge portion, both as it will be seen by the physician or 
technician using the device and with some surfaces slightly transparent so that the depth of the 
reagent reservoirs and the loaded pipette tips can be seen. The figure emphasizes the simplicity 
of the cartridge design. 
5.3.5 Clotting Surfaces 
 There will be four clotting surfaces on the device, 3 of which are different. The first and 
simplest surface will be a collagen surface, which is described by Colace2 and is summarized 
and reproduced in Appendix 13.4. The second will emulate the extrinsic clotting pathway: a 
collagen-tissue factor surface also described by Colace2 and again summarized and reproduced 
in Appendix 13.4. The third distinct surface will be a kaolin-collagen surface to activate the 
intrinsic clotting pathway, which previously has not been done. 
 The first attempt at a collagen-kaolin surface was performed in the laboratory on 
February 1, 2013 with the help of Tom Colace. Kaolin is a nonpolar clay mineral 
(Al2Si2O5(OH)4) and in when purchased as a powder, the size is not consistent and special 
consideration is taken when using kaolin as a reagent for our device. A kaolin mixture was 
created by adding 200 mg powdered kaolin to 5 mL HBS, stirring, and centrifuging briefly. The 
solution was allowed to settle overnight, and several distinct layers formed, shown in Figure 
5.27. Since the top and least cloudy layer contained what should be the smallest particles, this is 
what was used in the protocol. 
 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
70 
 
 
Figure 5.27: Kaolin mixed with water, centrifuged briefly, and allowed to settle overnight. Three distinct bands 
appeared within the solution, with the heavier particles at the bottom. For the kaolin-collagen surface, the top layer 
was used. 
 
 Within a microfluidic chip, collagen was diffused over the surface. Excess collagen 
solution was removed. A 0.5% BSA (bovine serum albumen) in HBS (HEPES-buffered saline) 
solution was diffused over the collagen and removed. Next, kaolin from the top layer of the tube 
was diffused over the collagen. This surface was observed under a microscope and is displayed 
in Figure 5.28. Figure 5.28a is a collagen-perfused surface, while figure 5.28b is a collagen-
kaolin surface. The collagen particles in figure 5.28b appear to be 'rougher,' suggesting that each 
collagen fibril is coated in the kaolin. Watching the microscope display in real time revealed 
kaolin diffused over the surface in a display of Brownian motion. 
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a.  b.  
Figure 5.28: a) Collagen surface, no kaolin. b) Collagen surface after perfusion of kaolin. The collagen-kaolin 
surface appears 'rougher' than the collagen surface alone. This suggests that the collagen particles are coated in 
kaolin. 
 Blood was collected from a donor and coagulation was inhibited immediately upon 
collection using a 4 μg/mL corn trypsin inhibitor (CTI), a Factor XII inhibitor. Fluorescent 
antibodies against platelets and fibrin were added to the blood and gently mixed. Immediately 
before perfusion over the surface, a solution of calcium chloride in HBS was added to the blood 
for recalcification. Blood was added to the wells on the microfluidic chip and pulled over the 
surface by pulling with a syringe pump to achieve a shear rate of 100 s-1 and a flow rate of 1 
μL/second. 
 The results were not indicative of success, since fewer platelets appeared to accumulate 
on the kaolin-collagen surface when compared with the collagen surface, Figure 5.29. The 
results are compiled in Figure 5.30, which plots fluorescent intensity as a function of time. Thus 
the two graphs can be used to determine the extent and time of onset of coagulation. The 
addition of kaolin to the collagen surface appears to have had no effect on the coagulation time 
on the chip. Additional experiments would be required. 
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a. b.  
Figure 5.29 Early platelet accumulation on the collagen surface (a) and the kaolin-collagen surface (b). Platelets 
are fluorescing in green. A more sparse accumulation of platelets is observed on the Kaolin-Collagen Surface. 
Images are taken from a compilation video of the on-chip coagulation event, which have been uploaded and can be 
viewed on Youtube3,4. 
a.  b.  
Figure 5.30: Accumulation of platelets and fibrin over time as blood diffused over both the collagen (a) and kaolin-
collagen (b) surface. Platelets are displayed by the black line with error bars defined by the standard deviation 
among 8 surfaces. Fibrin is displayed by the blue line with error bars defined by the standard deviation among 8 
surfaces. Platelet levels appear lower in the kaolin-collagen surface than the collagen surface. Fibrin begins to 
accumulate around the same time for both surfaces, around five minutes. 
 Additional consideration was made to determine the next steps in the creation of a 
collagen-kaolin surface that would promote coagulation better and 'faster.' The idea initially was 
considered since liposomes weakly adsorb to kaolin particles21, and liposomes had previously 
been used to target tissue factor to the collagen surface2. It is also known that lipids help to 
promote coagulation22. 
Kaolin-Collagen Surface 
Platelets  
Fibrin 
Collagen Surface 
Platelets  
Fibrin 
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 The next experiment in lab tested kaolin-collagen-lipid surfaces, dextran sulfate-
collagen-lipid surfaces, and collagen-lipid surfaces. Kaolin was prepared as described above. 
Before perfusion over the surface, liposomes with a composition of 80% phosphatidylcholine 
and 20% phosphatidylserine were added to the mixed and centrifuged kaolin in a 1:10 ratio. The 
mixture was perfused over a collagen surface and allowed to incubate for thirty minutes before 
perfusion with .5% BSA in HBS. Dextran sulfate was mixed to form a dilute mixture, mixed in 
the same ratio with the same lipid ratio, perfused over a collagen surface, allowed to incubate 
for thirty minutes, and then the channel was perfused with BSA. Similar techniques were 
applied for the control, collagen-lipid surface, except HBS was used in place of the kaolin or 
dextran sulfate mixture. 
 Figure 5.31 portrays the results of this experiment. All three surfaces are detailed, with 
the accumulation of platelets (a) and fibrin (b) indicated by the fluorescent intensity versus time 
for the duration of the coagulation event. It is readily observable that fibrin began to accumulate 
at the collagen-kaolin-lipid surface at a time of 3 minutes. This is about half the time the other 
two surfaces took to begin fibrin accumulation, and suggests a successful experiment. Figure 
5.32 is a snapshot of the fluorescence at t=5 minutes, which highlights that the fibrin 
accumulation on the surface is 20 times greater for the collagen/kaolin/lipid surface than it is for 
the collagen/lipid surface. It also suggests that platelet accumulation is comparable on all three 
surfaces. 
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a.  b.  
Figure 5.31 Accumulation of platelets (a) and fibrin (b) on collagen/lipid surface (black), collagen/dextran/lipid 
surface (red), and collagen/kaolin/lipid surface (blue).While platelets appearslightly repelled by the 
collagen/kaolin/lipid surface, fibrin accumulation began in almost half the time of the other two surfaces for the 
surface with kaolin. 
 
 
Figure 5.32 Fluorescent intensity of surfaces at t=5 minutes.Fluorescent intensity increases as platelets or fibrin 
accumulation increases. While platelet accumulation appears similar on all three surfaces, fibrin accumulation on 
the collagen/kaolin/lipid surface is twenty times greater than on the collagen/lipid surface after five minutes of 
flow. 
 This early clotting event is vastly useful in the Microfluidic Multi-Surface Coagulation 
Assay Chip, since measurements for all three surfaces can be used to determine the extent of 
clotting at a time as early as after 5 minutes of flow. Devices or blood assays currently on the 
market take much longer to measure coagulation time. 
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Chapter 6: Microfluidic Device Design Principles  
6.1 Introduction 
Highly precise fabrication techniques are required to manufacture channels that are only 
up to 300 micrometers in width. Additionally, because fluid is difficult to characterize at such a 
small length scale, the microfluidic device must be made with material that will not interact 
with the reagents that pass through it. As mentioned in Chapter 5, the Microfluidic Multi-
Surface Coagulation Assay device will have two components – a cartridge and a chip. The 
cartridge is made of plastic and is used for the storage of dye and buffer solutions as well as 
pipette tips. The chip, in turn is comprised of a glass slide bonded to the molded elastomer 
poly(dimethylsiloxane), or PDMS. The PDMS layer contains the pattern of the microfluidic 
channels and the glass layer contains the four clotting surfaces. To pattern the PDMS, soft 
lithography was chosen as the method for replica molding and rapid prototyping. Soft 
lithography requires a master mold which is in turn constructed through photolithography. To 
deposit the clotting surfaces onto the glass chip, a method of microdispensing is necessary due 
to the small amount deposited. Precision printing using ink-jet technology was chosen due to 
the speed, precision, and digital nature of the technology that makes it suited for automated 
control in a manufacturing setting.  
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6.2 PDMS 
Fabrication of microfluidic devices using polymers is relatively simple and reduces the 
cost, complexity, and time of manufacturing. PDMS is a widely used elastomer in microfluidics 
due to its many beneficial properties. The structure of PDMS consists of repeating –OSi(CH3)2 – 
units as shown in Figure 6.125. Depending on the number of repeated units, the viscosity of 
PDMS can be altered. PDMS has the ability to allow for features with dimensions as small as 
0.1 micron to be accurately fabricated, allowing for detailed designs of the channels within our 
device. Moreover, PDMS is nontoxic as well as thermally and electrically insulating and non-
reactive with the reagents used in the Microfluidic Multi-Surface Coagulation Assay. PDMS is 
inert, meaning it is nor reactive toward most reagents. However, PDMS can be oxidized through 
exposure to plasma, which is a crucial step in the chip manufacturing process. In addition, the 
Microfluidic Multi-Surface Coagulation Assay tests for fibrin and platelet presence in blood 
with light, and PDMS permits for optical detection from between 240 to 1100 nm, allowing 
flexibility in the design of our device. PDMS is also widely available for purchase in bulk and is 
relatively inexpensive and the manufacturing procedure can be conducted without an expensive 
Figure 6.1 The atomic and molecular 
structure of PDMS, composed of 
repeating polymer music (2). 
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clean room. Finally, PDMS can be irreversibly sealed to another surface if both are Si-based 
materials and have been oxidized by plasma before contact, making it ideal to be sealed to the 
glass chip26.  
PDMS is supplied in two components, a base and a curing agent, and the first step in 
creating a PDMS microfluidic device is to mix the two which results in the silicon hydride 
groups in the curing agent reacting with the vinyl groups in the base, causing polymerization 
and forming the desired elastomeric solid. The components are mixed, usually in a 10:1 ratio of 
base : curing agent and subsequently poured over a master, which is made from 
photolithography. Patterning of the PDMS with the desired microfluidic structures occurs when 
the liquid PDMS pre-polymer then conforms to the shape of the mold and replicates it with 
fidelity within 10 nanometers after curing through a process known as soft lithography. PDMS 
has low surface free energy and its elasticity also allows it to be removed from the master 
without damaging either the mold or itself24.  
6.3 Photolithography 
 In order to manufacture PDMS with the desired design of the microfluidic device, a 
master mold needs to be made with the reverse pattern of the mold. The master mold is made 
using photolithography – a method commonly utilized in the field of electronics. Through 
photolithography, geometric shapes are transferred from a mask to the surface of a silicon 
wafer. The steps of photolithography include: spin coating, soft bake, exposure, post exposure 
bake (or hard bake), and development. A light sensitive substrate, or photoresist, is deposited on 
a photomask and exposed to UV light. Both positive and negative photoresists can be used. For 
positive resists, exposure to UV light causes the structure of the resist to change so that it is 
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more soluble in the developer and thus positive photoresists are added to the photomask 
wherever the underlying material needs to be removed. Negative photoresists are exactly 
opposite, exposure to UV light initiates cross-linking in the photoresist and thus it does not 
dissolve 27. Figure 6.2 shows the pathway of both positive and negative photoresists. The 
Microfluidic Multi-Surface Coagulation Assay utilizes a negative photoresists in the 
development of the master mold. 
For our device, a photomask designed using SolidWorks, a computer-aided drawing 
(CAD) program is laid on top of a silicon wafer. Since a negatively charged photoresist is used, 
the mask contains the inverse of the desired pattern to be transferred. The photoresist used to 
create the experimental molds is the KMPR ® 1000 by MicroChem. The photoresist is deposited 
Figure 6.2 The process of 
photolithography to make a master 
mold using a photosensitive resist and 
exposing it to light (4). 
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onto the silicon and spin coating is used to deposit the layer evenly onto the wafer with the 
speed and time of spinning dependent on the desired height of the mold. The spinning starts 
slowly, around 500 rpm and increases up to 3000 rmp. Next, a soft bake step occurs to slightly 
harden the surface and the length of baking time is also dependent on the thickness of the layer. 
In the case of the Microfluidic Multi-Surface Coagulation Assay, 60 microns was the target 
thickness and the soft bake time is approximately 20 minutes at 100⁰C29. 
The next step in photolithography is exposure, where the photoresist is exposed to high 
intensity ultraviolet light. Alignment of the photomask and the silicon wafer is critical for the 
success of this step. Three primary exposure methods are contact, proximity, and projection and 
Figure 6.3 illustrates the relative positions of the light source, the optical system, the mask, the 
photoresist and the silicon wafer for each method. Contact lithography was chosen because high 
resolution is possible due to the contact between the photomask and the photoresist. During 
contact lithography, cross-linking occurs in the negatively charged photoresist everywhere the 
Figure 6.3 Representation of the three different types of photo lithography: contact, 
proximity, and projection (4).  
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light shines through the mask. Full contact is vital because the light could shine beneath the 
mask if it is not achieved, and the imprint will be compromised. As with the spin coating and 
soft bake steps, the exposure energy is related to the thickness of layer.  
Directly after the exposure step is the post exposure bake where the photomask is 
removed and the silicon wafer is baked for 4 minutes at 100⁰C. The final bake is necessary to 
harden the photoresist and improve its adhesion to the silicon surface. The final step is 
development, where the un-polymerized areas of photoresist are removed from the wafer, 
leaving only the desired pattern behind. And aqueous alkaline developer, tetramethylammonium 
hydroxide (TMAH), removes the untreated areas upon immersion and strong agitation. The 
develop time is around 8 minutes for our desired thickness and it is during this step that the 
patterns of the mold become visible. After development, the master mold can be used once it 
has been rinsed and dried. With proper care and handling, a single master mold can be the basis 
for hundreds of PDMS molds from soft lithography29. In Figure 6.4, an example of successfully 
deposited photoresist on a silicon wafer is shown.  
There are some limitations and precautions that must be considered with 
photolithography. This process cannot be used to create precision to the nanometer scale 
because it is limited by the wavelength of the UV light used. Additionally, more complex 
patterns such as pyramidal shapes or concaves within the thickness of the photoresist are more 
difficult to achieve. Other important considerations that could affect the quality of the mold 
include the humidity of the environment, bubbles forming in the resist solution and the ambient  
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light that could affect the sample. It is best to work in a clean room when creating a master mold 
and filtering out lights that could affect the sample can prevent failed molds. After the 
successful creation of a master mold, the next step in manufacturing the chip is to create a 
PDMS replica from the mold.  
6.4 Soft Lithography 
In order to reach our manufacturing goal of 1 million devices per year, soft lithography 
was chosen as the method for rapid replica molding. Numerous methods of pattern transfer from 
master mold including contact printing and embossing. Replica molding was chosen for its 
advantages in mass production. Replica molding is the duplication of information such as shape, 
morphology and structure that is present in a master mold. Soft lithography offers a wide range 
of usable materials and has the advantage of being able to duplicate three-dimensional patterns 
Figure 6.4 Images of the 
microfluidic PDSM patters that 
were used for research behind 
the scenes. Picture quality is 
due to the reflective nature of 
the mold. 
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in one step. Highly complex topologies in the master mold can be accurately replicated onto 
numerous copies in a process that is simple and inexpensive. The elastomer used in this process 
is PDMS, which, in addition to the beneficial properties stated earlier, also has the ability to 
conform to the surface of a substrate over a relatively large area, and the elastic characteristic of 
PDMS allows it to be easily removed from the mold, even from complex patterns. PDMS is also 
durable, and thus ideal for manufactured products which may not be used immediately31. 
The replica is made by first pouring the PDMS, which consists of the mixture of base 
and curing agent, over the master mold. Subsequently, the PDMS solidifies under exposure to 
high temperatures and conforms to the shape of the mold. After enough time has passed to 
solidify the PDMS, it is peeled from the master to reveal the final pattern of the microfluidic 
device. When the PDMS is fixed to a glass slide, it creates the microfluidic channels, and 
together the two components create the microfluidic device. Figure 6.5 shows the steps of the 
soft lithography process on an extremely simplified model. 
Figure 6.5 A simplified version of the 
PDMS manufacturing steps of pouring 
PDMS over photoresist, thermal curing, 
and then adhesion to the glass plate (7). 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
83 
 
 The main advantage of replica molding soft lithography is that many PDMS replicas can 
be constructed in parallel, which is extremely beneficial in a manufacturing setting. Features 
smaller than 100 nm have been accurately replicated, which is much more detailed than our 
microchip design. Figure 6.6 shows an example of a PDMS layer created from them master 
mold that has been mounted onto a glass plate and is now ready for laboratory use. Soft 
Lithography also has a number of properties that must be addressed and considered. First, 
PDMS shrinks by around 1% after curing, and experimental testing is necessary to ensure 
repeatability of theoretical models. Also if the aspect ratio (length to height) ratio of the PDMS 
features is too small or too large, then pairing or sagging can occur. These conditions can be 
seen in Figure 6.7. Laboratory testing can ensure that our designs produce repeatable, durable, 
and accurate replicas despite these potential disadvantages31. With the successful fabrication of 
the PDMS layer of the chip, the next step is to consider the deposition of the clotting surfaces 
onto the glass slide. 
 
 
6.5 Clotting Surfaces – Ink-Jet Fluid Handling 
Figure 6.7 Possible disadvantages of 
PDMS include a) sagging, and b) 
shrinking (4). 
Figure 6.6 A lab-grade microfluidic 
device that is attached to the glass slide 
beneath it 
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The design of the Microfluidic Multi-Surface Coagulation Assay calls for four clotting 
surfaces to be deposited onto the surface of the glass chip. Since only 3 surfaces are planned to 
be tested, the fourth surface will be a replica of one of the surface and be available for future 
tests. The three tested surfaces are: collagen, collagen with kaolin and lipid, and collagen with 
tissue factor. The collagen acts as a substrate for platelet deposition while the two other surfaces 
simulate the intrinsic and extrinsic clotting pathway. Over the years, miniaturization of 
electronic and photonic devices has increased the productivity of biomedical devices, but the 
physics of fluid dispensing at such small quantities can limit the degree to which miniaturization 
can occur. The microdispensing technique chosen for our device is ink-jet fluid handling. 
Widely used in printing today, ink-jet fluid handling has been increasingly used for 
microdispensing and precision printing for adhesives, liquid solder, optical and electrical 
polymers, and biomedical materials such as diagnostic reagents, proteins and DNA33. Ink-jet 
fluid handling dispenses fluid in two manners: continuous and drop-on-demand. Continuous 
dispensing, fluid constantly flows through an orifice with an electrochemical device that creates 
pressure oscillations that break the fluid into droplets of equal size. The droplet breaks from the 
stream in the presence of a charging field and thus acquires and electrostatic charge. Another 
electrostatic field, known as the deflection field, directs the drops to their desired locations. 
Figure 6.8 shows an image from a continuously dispensing system. Drop-on-demand, or 
Figure 6.8 Continuous dispensing with 
ink-jet printing that results in multiple 
droplets of equal sides9. 
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demand mode, a volumetric change in the fluid occurs when a voltage pulse is applied to a 
piezoelectric material that is either directly or indirectly coupled to the fluid. The resulting 
volumetric change causes a pressure or velocity  
 
 
 
change in the fluid and leads to the production of a single drop from the opening. Figure 6.9 
shows images from a drop-on-demand system. Since a drop will only appear when voltage is 
applied, demand mode is also more easily adjusted for our specifications. The ink-jet handling 
system has the capability of delivering droplets 80-100 times per second32.  
6.6 Adhesion of Glass to PDMS – Plasma Oxidizer 
In order to complete the chip, the PDMS layer that has been patterned with the 
microfluidic channels must be bound to the glass slide after the four clotting surfaces had been 
deposited. PDMS has the ability to bond both reversibly and irreversibly to a surface. For our 
device, irreversible sealing is necessary. For irreversible sealing, the surface must be exposed to 
oxygen plasma34. When oxidized, the PDMS and glass form covalent O-Si-O bonds. The seals 
are watertight and can be formed without high temperatures or other adhesives. In many 
microfluidic devices, only the PDMS receives oxygen plasma treatment, and not the secondary 
surface. But in the case of our device, if the PDMS undergoes oxygen plasma treatment and is 
placed over the clotting surfaces, then the surfaces might be affected. So since PDMS can be 
irreversibly sealed to another surface if both are Si-based materials and the surface has been 
Figure 6.9 Demand mode ink-jet printing 
where only a small amount is needed with 
great accuracy 9. 
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oxidized by plasma before contact, the glass slide will undergo oxygen plasma treatment first 
before the surfaces are deposited26.  
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Chapter 7: Manufacturing  
7.1 Introduction 
The Microfluidic Multi-Surface Coagulation Assay will mainly be manufactured within 
our own facilities. The device is made of two components – the cartridge and the chip. 
Additionally, the processing unit structure into which a disposable device can be inserted and 
analyzed must also be sold to customers. The plastic cartridge is a relatively simple design and 
will be manufactured separately. The processing unit will also be outsourced due to our limited 
understanding of the electronics and electrical engineering necessary to design a fully functional 
processing unit. The idea of outsourcing was not considered for the chip component of the 
device due to the importance of protecting the intellectual property by maintaining complete 
control over its fabrication. The device fabrication and the loading of reagents into the cartridge 
as well as the final sealing and packaging steps will all take place within our manufacturing 
facility.  
Initially, the manufacturing will proceed with manual labor during the prototype phase 
and then move onto automated processes with human operators. In our manufacturing facility, 
there will be three main pathways that converge into the completed device. First there is the 
chip, which in its own fabrication contains two manufacturing lines: the PDMS layer and the 
glass slide. The PDMS layer must be molded and the clotting surfaces must be deposited on the 
glass slide. Then the PDMS layer and the glass slide must be bonded together. The cartridge is 
its own separate path where calcium buffer and dye are deposited and pipet tips are loaded into 
the plastic shell. Finally, the chip and the cartridge are put together and packaged as the final 
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device. The success of the device depends on the speed and accuracy of our manufacturing, 
especially to keep up with our goal of 1 million devices per year.  
7.2 Manufacturing Overview 
At 10 percent market penetration, the goal is to produce 1 million chips per year. Certain 
parameters and assumptions about the manufacturing facility must be made in order to 
determine the number of chips that need to be manufactured in one work day in order to meet 
the market capture goal. The first assumption is that the manufacturing facility will operate for 8 
hours a day for 330 days per year. Equation 7.1 shows that the number of chips that must be 
manufactured in one day is approximately 3,031. 
1,000,000 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟330 𝑑𝑎𝑦𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 = 3030.333 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 
After working with our industry consultant, the next assumption we made is that 1 
percent of the chips made will be used for quality assurance testing. This number was set due to 
the large number of chips manufactured in one day as well as the projected reliability of the 
manufacturing process. Since the chips that are manufactured are transparent, quality inspection 
could simply be a visual test and those chips that are deemed suitable could still be counted 
towards the total chips needed to be produced in one day. However, we decided to follow a 
more conservative approach and assume that all chips that are needed for quality assurance 
testing will not be counted towards the 3,030 chip goal. As a result, in order to produce 3,030 
chips for sale, a total of 3,061 chips must be manufactured (see Equation 7.2). 
3030.33 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 × (1 + 0.01 𝑞𝑢𝑎𝑙𝑖𝑡𝑦 𝑎𝑠𝑠𝑢𝑟𝑎𝑛𝑐𝑒) = 3060.66 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 
7.1 
7.2 
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Finally, the possibility of failures and defects must be taken into account when outlining 
a manufacturing plan. According to our industry consultant, a 1 percent failure rate, or 99 
percent success rate would be an appropriate assumption. Taking these estimations into account, 
3,092 chips must be manufactured in one day in order to reach the goal of 3,031 chips 
manufactured for sales, Equation 7.3. This number is further broken down into six batches of 
516 chips that will be manufactured throughout the day. The exact methodology of the 
breakdown is discussed later in this chapter. 
3036.66 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 × (1 + 0.01 𝑓𝑎𝑖𝑙𝑢𝑟𝑒) = 3092.21 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 
This division results in the manufacturing of a few excess devices but the number was chosen so 
that each batch contains the same number of chips and the manufacturing process is consistent. 
The exact methodology of the breakdown is discussed later in this chapter. This manufacturing 
process is able to successfully accommodate batches of 516 chips and fit six batches into an 8 
hour work day.
7.3 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
90 
 
 
 
  
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
91 
 
Finally, the actual manufacturing plan must be determined, and in order to accurately 
gauge the cost of manufacturing, the roles and numbers of employees were considered. Figure 
7.1 provides a simplified model of the steps in the manufacturing facility, as well as an 
overview of the equipment required. The details of the equipment selection as well as the timing 
of the manufacturing day will be presented in subsequent sections of this chapter. Figure 7.1 
also shows the breakdown of labor on the manufacturing floor. Since the process is automated, 
a single operator can oversee several machines within the manufacturing line, and thus it was 
determined that 5 workers would be needed to oversee the manufacturing. Further employment 
was also considered and the final roster of necessary employees is shown in Table 7.1. A 
breakdown of the wages and compensations that were used to determine the total labor cost of 
manufacturing can be found in Appendix 13.5. 
Job Number Wage (total) 
Manufacturing Workers 5 $274,600.00 
Quality Assurance 1 $92,780.00 
Maintenance 1 $41,110.00 
Supervisor 1 $114,490.00 
Engineer 1 $92,260.00 
Sales/Marketing 1 $84,510.00 
Field Reps 3 $287,250.00 
Research and Development 3 $312,180.00 
Clinical Trial Manager 1 $96,380.00 
Total $1,395,560.00 
Total with Compensation/Benefits (1.5x) $2,093,340.00 
 
 
 
 
Table 7.1 Labor expenses and compensation for the manufacturing process of the µMCA 
with employment data found from the Bureau of Labor Statistics 
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7.3 Fabrication of Microfluidic Chip 
The microfluidic chip is where the chemical interaction between the blood sample and 
the clotting surfaces occurs. The microfluidic channels are patterned onto the PDMS layer. As 
mentioned in Chapter 6, PDMS was chosen as the elastomer for the microfluidic device due to 
its numerous beneficial properties, from its optical transparency to the targeted wavelengths to 
its chemical stability and low level of interaction with reagents. 
During a typical manufacturing day, the PDMS solution is prepared first. The two 
components of PDMS, the base and the curing agent, must be first mixed. A 10:1 ratio of base 
to curing agent is used and after mixing at low rpm for 10 minutes, the PDMS is ready to be 
used in manufacturing. Since approximately 35mL of PDMS is used for each device, a 120 tank 
is used to store the PDMS in the factory. The excess space is for further manufacturing needs or 
future expansion. In Chapter 5, soft lithography was detailed and will serve as the method for 
rapid production of the PDMS layer. The soft lithography will be based off of a master mold 
made using photolithography. Only a few of these masters need to be made. The channels each 
have a height of 60 µm and the lengths of the channels vary from hundreds of microns to 
centimeters, which all fit within the parameter for photolithography. Once the master molds are 
created using a negative photoresist, a PDMS ‘stamp’ can be created. A stamp is a PDMS layer 
that contains the inverse of the final pattern and these stamps will in turn be used for the actual 
manufacturing processes. In order to achieve the goal of manufacturing 3,091 devices in one 
day, hundreds of these PDMS stamps can be used in parallel to mold the PDMS for the actual 
devices. PDMS stamps can be used to create accurate patterns for greater than 10 uses, so it is 
assumed that, at most, new stamps would have to be created once per week36. After the PDMS 
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is poured into the mold, it undergoes thermal curing by heat treatment in an oven for 1 hour in 
order to create structurally stable layers. 
The oven that the molds are placed in must be large enough to accommodate all of the 
molds and maintain a temperature of 80⁰C. At any time, there will be a maximum of 516 PDMS 
molds inside the oven given our current manufacturing pace. A suitable oven was found in a 
previous senior design project by Abbot, Lee, Kohli and O’Brien. The curing oven is produced 
by the Wisconsin Oven Corporation and its inside area is approximated to be 60 ft2. In order to 
accommodate 516 PDMS molds, less than 20 ft2 is required (specific sizing calculations can be 
found in Appendix 13.6). Purchasing a large oven allows for the possibility of larger batch sizes 
in the future as production expands. The curing oven is priced at $22,400, which was deemed 
reasonable by our industry consultants and thus is used in our cost estimation.  
Following the removal of the PDMS molds from the oven, the newly-cured PDMS 
layers are separated from the molds. This process is assumed to be trivial and will not require 
any chemical or thermal aid because one of the favorable properties of PDMS is its ease of 
detachment. Next, in order to create the larger reservoirs for both the deposition of the blood, 
dye, and the waste reservoir in the device, a hole-punching machine will be utilized. The hole-
punch machine is estimated to cost $20,000. After this step, the PDMS layer is complete and 
ready for bonding with the glass slides coated with clotting surfaces37. 
The second manufacturing component of the chip is the coagulation surfaces on the 
glass slide. Because of the sensitive nature of the surfaces that are deposited on the glass slide, it 
was decided that the oxygen plasma treatment of the glass slide will occur before the surfaces 
are deposited. The glass slides are laboratory-grade, and the cost of the oxygen plasma 
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treatment machine is estimated to be $45,00038 and in order to successful treat all 516 slides is 
estimated to be 30 minutes. After oxidation, the four clotting surfaces are deposited onto the 
slide using ink-jet printing technology, described in Chapter 5. After consulting with David 
Wallace of MicroFab Technologies, Inc, it was decided that a full ink-jet printing system would 
be purchased with four separate print heads for the four surfaces. The full quotation can be seen 
in Appendix 13.7, and the total cost of the JL4-xl printing system with the PH-46 print heads is 
estimated to be $68,550. The full process of depositing the surfaces onto the surfaces is 
estimated to take 1.5 hours based on our laboratory experiments.  
After the surfaces have been deposited on the oxidized glass slide, an adhesion process 
must occur to bind the PDMS to the layer to the glass slide. A favorable property of PDMS is 
demonstrated in this step as the only step required for adhesion is contact between the PDMS 
layer and the glass slide for 30 minutes39. After the adhesion process is complete, the chip is 
ready to be packaged along with the cartridge.  
7.4 Cartridge Assembly and Packaging 
Though the cartridge body will not be manufactured in our facility, reagents such as the 
dye and buffer need to be added to the cartridge before packaging and pipette tips also need to 
be delivered. A robotic liquid handling system was chosen to deliver the reagents to the 
cartridge. The robotic liquid handling system is estimated to cost $60,000. It is assumed that it 
will take 2 seconds to deposit the reagents into each cartridge body so 30 minutes have been 
allotted to completing the reagent deposition in all 516 cartridges. The delivery of pipette tips 
into the cartridge is also automated and the delivery of four standard-sized pipettes into the 
cartridge is estimated to take 2 seconds as well, meaning another 30 minutes is allotted for this 
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step, and the cost is estimated to be $30,000. The final step in the cartridge manufacturing 
process is the foil sealing of reagents. The seal prevents contamination of the reagents and the 
physicians or technicians will remove the seal in order to deposit their blood sample into the 
cartridge. After looking at a range of foil-sealing machines, it was estimated that foil-sealing 
will cost $7,500 and need 1 hour to completely seal all of the cartridges.  
Finally, when all the components of the device are complete, the final step is packaging. 
Our device will be individually sealed and packed into customized boxes. After consulting with 
Imperial Printing & Paper Box MFG, it was determined that the yearly cost for packaging is 
$23,971 with a one-time designing fee of $590, the full quote can be found in Appendix 13.8. 
After the chips have been packaged, they are placed in a large -80°C freezer for storage until 
they are removed for shipment or quality assurance testing. This last step is estimated to take 30 
minutes, which puts the total time for manufacturing one 516-device batch at approximately 3 
hours, since many of the steps occur in parallel.  
7.5 Manufacturing Timeline 
At approximately 10 percent market capture, 1 million devices need to be manufactured 
in 1 year. According to our assumed operation conditions of 330 days a year and 8 hours a day, 
3,090 chips must be manufactured in one day, accounting for defects and quality testing as 
mentioned in the previous sections. In order to determine the number of batches needed and the 
number of devices per batch, a breakdown of the manufacturing of one batch is needed. Figure 
7.2 shows the breakdown of the manufacturing. The PDMS manufacturing steps include the de-
gassing of the PDMS mixture and the thermal curing in the oven. Both processes are 1 hour so 
the total time required is 2 hours. The treatment of the glass slide requires 30 minutes and the 
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deposition of the clotting surface onto the slide needs 1.5 hours so the total process also takes 2 
hours. Since these two are independent processes, they can occur in parallel and after 2 hours 
both will be ready for the adhesion process, which takes 30 minutes, meaning that the chip of 
the device is complete after 2.5 hours of manufacturing. The cartridge manufacturing also 
occurs separately, with both the reagent and pipette deposition taking 30 minutes for a total of 1 
hour. The foil-sealing process also takes 1 hour so the cartridges are prepared after 2 hours. The 
packaging step takes place at the 2.5 hour mark and takes 30 minutes, rounding off the 
manufacturing process at a total rate of 3 hours per batch. 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
97 
 
 
 
  
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
98 
 
In one 8-hour workday, all 3,090 chips must be manufactured. The manufacturing 
process can be thought of as a series of batch-like reactions because many of the process can 
only handle one batch at a time. After analyzing the timeline of producing one batch, the limit 
of this manufacturing process is the curing oven. A new batch of PDMS molds can only be put 
into the oven once the curing process of the previous batch has been completed. This means that 
the manufacturing process of the next batch cannot start until one hour after the previous batch. 
Assigning the beginning of the work day as hour 0, and taking into account the three hours that 
are required for a batch to be complete, the last batch must begin the process at hour 5. So a 
total of 6 batches can be completed in one day. Equation 7.4 can then be used to calculate the 
number of chips that need to be in each batch. 
3,092.21 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦
6 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 𝑝𝑒𝑟 𝑑𝑎𝑦 = 515.368 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ ≅ 516 𝑑𝑒𝑣𝑖𝑐𝑒𝑠 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ 
 Six batches per day of 516 devices per batch is the final breakdown of the 
manufacturing plan. The overlapping of multiple batches allows the manufacturing to be 
complete in one working day. Figure some just shows a diagram of the manufacturing 
breakdown with each of the steps of the chip and cartridge manufacturing collapsed into one 
continues time. 
7.4 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
99 
 
 
 
 
  
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
100 
 
Chapter 8: The µMCA Development Timeline 
8.1 Introduction 
 Upon completion of the design of The Microfluidic Multi-Surface Coagulation Assay, 
we project that the device can be market ready in one year. The time is divided between FDA 
approval as well as Clinical Trials and prototyping. 
8.2 Product Development and Prototyping 
 Results in lab provide us with confidence that clinical trials will go well and ensure 
more rapid and useful testing than other devices or tests currently in the market. Additionally, 
during the phase of clinical trials, it can be confirmed that specific design features such as the 
applied pressure drop are optimal for measurement of coagulation. If necessary, during this one 
year timeframe, features such as the pressure drop can be modified for optimal measurements.  
 The clinical trials are also important since these data will be used as a standard for 
assessing patient blood samples once the µMCA is in the marketplace. The average 
fluorescence values from healthy patients will be considered ‘normal’ or ‘average,’ and 
deviations from this value will indicate coagulation dysfunction and can be used to determine 
treatment options. We will standardize the device output information so that physicians are able 
to receive consistent and accurate diagnostic data. Since the output will be a number and can 
easily be compared to ‘normal,’ the µMCA will be appealing to not only doctors but insurance 
companies who value standardized approaches to medicine. 
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8.3 FDA Regulations and Approval 
 The Microfluidic Multi-Surface Coagulation Assay will be treated as a medical device in 
the US market since its use will affect patient treatment in a hospital setting or possibly affect 
the outcome of clinical trials. The FDA classifies medical devices as Class I, II, or III depending 
on the level of control that must be associated with device production and regulation in the 
marketplace42. Class I devices require the least controls and do not pose risk to patients or users. 
Examples of Class I devices include bandages and medical examination gloves42. Class II 
devices require special controls beyond the basic ones required for Class I devices, and typically 
require some degree of equivalence to a device already legally in the market. Class III devices 
require the most stringent controls, since their uses often support life or could cause life 
threatening results for patients42. Class III devices require Premarket Approval which confirms 
safety and efficacy of these devices42. 
 Based on the FDA website, The Microfluidic Multi-Surface Coagulation Assay will be 
classified as a Type II device. The device is most likely classified as a "Multipurpose system for 
in vitro coagulation studies," defined in the Code of Federal Regulations Title 21 Volume 843. 
To ensure correct device classification, a prototype as well as manufacturing protocols and 
design specifications must be sent to the FDA. 
8.4 Clinical Trials 
 In order to achieve approval of The Microfluidic Multi-Surface Coagulation Assay, 
rigorous clinical trials must take place to prove safety and efficacy of the product. An 
Investigational Device Exemption (IDE) must be filed before clinical trials begin. This process 
entails approval by an institutional review board (IRB), informed consent from all patients, 
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labeling denoting that the product is for investigational use only, observation of the study, and 
thorough records and reports45. 
 For all trials, patients will provide one blood sample a week for four weeks. Each 
sample will be tested 3 times using The Microfluidic Multi-Surface Coagulation Assay to 
ensure self-consistency of results. Additionally, the blood will be tested using the competitor, 
the INNOVANCE PFA-200 System by Siemens, as well as the traditional activated partial 
thromboplastin time (aPTT) test to compare results and applicability of the results. 
 We estimate that the Clinical Trials as outlined will cost $3MM. When combined with 
the estimated $500K for FDA approval including legal advice, the cost to bring the device to 
market totals $3.5MM. 
8.4.1 Phase I 
 One hundred patients will participate during Phase I clinical trials, which will span 1 
month. The purpose of this stage is to prove initial effectiveness, and to avoid major capital 
losses a small number of patients will be tested. Each patient in this stage is healthy, thus 
establishing a basis for comparison to unhealthy patients or patients being treated for a clotting 
abnormality. The data will be compiled and analyzed. Ultimately this stage proves repeatability 
of tests and a basis for further tests. 
8.4.2 Phase II 
 Three hundred patients will participate during Phase II clinical trials, including healthy 
patients as well as patients with clotting abnormalities and patients on anticoagulants and 
promoters of coagulation. Phase 2 will span 3 months and ultimately enable comparisons 
between the healthy patient base readings and patients with clotting disabilities.  
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8.4.3 Phase III 
 1000 patients will participate in Phase III clinical trials. The goal of phase III is the goal 
of the entire process: proof that the device is market ready. A large number of patients will 
participate with the same regular interval testing. Six months are allotted for Phase III clinical 
testing. 
8.5 Preparations for the Marketplace 
 Subsequent to the completion of clinical trials and while waiting for FDA approval to 
come through, or during months 11 and 12, preparations will be made for manufacturing. Steps 
to achieve this include renting a factory space, establishing relationships with vendors for 
reagents, and preordering equipment for manufacture. Following the steps outlined here will 
bring the device to market within 1 year of the completion of design. 
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Chapter 9: Financial Analysis 
9.1 Introduction 
The Financial Analysis of this project is focused on the costs and revenues in the 
development and production of the chip. Other forms of revenue such as technical support 
contracts and sales of the processing units are not considered in this analysis. This section will 
discuss market shares, costs, and operating assumptions and then discuss product viability in the 
market.  
9.2 Market Share and Sales Projection 
The rest of 2013 has been allocated to further development of this product. Another year 
has been allocated for the FDA trials and filing discussed in Chapter 8. As we wait for approval 
the manufacturing site will be found, leased, and fitted with the necessary machinery. This is 
another year; therefore production begins the year 2016. The price for each chip is assumed to 
be the pre-discount cost of $100/chip. An inflation rate of 2.4% was used and was calculated 
from an average of the inflation rates for the years 2003-201346. It has been assumed that we 
would capture 5% of the market in the first year of production. This number would increase to 
7.5% in the second year of production, and finally reaching an asymptote at 10% in the third 
year of production. Calculations can be found in the Appendix Section 13.3. The expected 
revenues for the ten years after filing are shown in Table 9.1. Expanding the market will add 
additional costs due to increased production needs. These costs are not reflected in the further 
financial analysis but are however taken into consideration in Section 9.8, which talks about 
expansion. 
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Year Revenues % Market Penetration 
2014 0 0 
2015 0 0 
2016 $107.3 5 
2017 $110.0 7.5 
2018 $168.8 10 
2019 $230.5 10 
2020 $295.1 10 
2021 $302.2 10 
2022 $309.4 10 
2023 $316.9 10 
 
9.3 Costs Sheets 
 Manufacturing the Microfluidic Multi-Surface Coagulation Assay includes various 
costs, such as the cost of cartridge and the processing unit, laboratory space, and clinical trials. 
The costs associated with the production of the cartridge and processing unit are compiled 
below. 
The costs associated with manufacturing the cartridge, including shift operators, 
facilities, equipment, raw materials, etc. can be found in Appendix 13.3 in the Financial 
Analysis Tables. For the manufacture of the cartridge it is estimated that we need approximately 
10,000 ft2 for manufacturing space, lab space, and office space. The cost of renting a 10,000 ft2 
office space in the Philadelphia area is approximately $150,000/yr or $15/ft2/yr 46. Extrapolating 
for the added costs of retrofitting existing office space for manufacture and laboratories, we 
estimate that renting a facility for our purposes would cost $500,000/yr. Other expenses 
included in the $500,000/yr include facilities items such as a cafeteria, a gym, break rooms, etc.  
Table 9.1: Total Projected Revenues with base case assumptions. Revenues in Millions 
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Since the product is targeted for use as a medical device, clinical trials need to be 
performed to prove efficacy as discussed in Chapter 8. As mentioned in Chapter 8, the 
estimated cost of FDA and Clinical trials is $3.5M.  
9.3.1  Costing the Chip 
 The cost of the materials in the chip itself was determined in a variety of ways. The 
prices of specialized materials, such as tissue factor or antibodies against collagen type 1, were 
determined from various source websites. The costs for more generic, lab-grade reagents were 
determined from sources such as Sigma Aldrich. These sources are not tailored for bulk 
ordering of reagents, but for the scale of individual research laboratories, so the prices are 
slightly overstated. However, it is assumed that this overstatement is negligible since costs are 
already so low due to the small volumes per chip, and the chip will be sold at such a high 
markup from the material costs. Table 9.2 summarizes the costing analysis, with a net cost of 
materials per chip around $1.16. For the projected 106 chips per year goal, the materials for all 
chips in a year will cost $1.6 million. 
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Item Price Per Unit (dollars) Unit Price How much Cost per device (Dollars) Source Date Priced
Calcium Chloride 215 2.5 kg 86 per kg 0.137 mg/device 1.18E-05 Sigma Aldrich 2/14/2013
Magnesium Chloride 214 1 kg 214 per kg 4.71E-02 mg/device 1.01E-05 Sigma Aldrich 2/14/2013
Zinc Chloride 5720 1 kg 5720 per kg 6.74E-05 g/device 3.85E-04 Sigma Aldrich 2/14/2013
Collagen 220 1 mL 220 per mL 0.9 ul/device 0.198 ChronoLog 2/14/2013
Sodium Chloride 184 5 kg 36.8 per kg 5.79E-05 g/device 2.13E-06 Sigma Aldrich 2/14/2013
Sodium Hydroxide 146 1 kg 146 per kg 2.93E-06 g/device 4.28E-07 Sigma Aldrich 2/14/2013
sodium phosphate dibasic dihydrate 106.5 1 kg 107 per kg 1.96E-06 g/device 2.08E-07 Sigma Aldrich 2/14/2013
HEPES 499 1 kg 499 per kg 8.69E-05 g/device 4.34E-05 Sigma Aldrich 2/14/2013
Distilled Water NEGLECT FACTORY 2/14/2013
Tissue Factor 12322 1 mg 12322 per mg 4.03E-06 mg/device 4.97E-05 American Diagnostica (former) 2/14/2013
BSA 5000 10 kg 500 per kg 5.14E-05 g/device 2.57E-05 Santa Cruz Biotechnology, inc 2/14/2013
Kaolin 152 2.5 kg 60.8 per kg 1.20E-07 kg/device 7.30E-06 Sigma Aldrich 2/16/2013
Heart PC (L-α-phosphatidylcholine (Heart, Bovine)) 2060 1000 g 2.06 per mg 1.24E-03 mg/device 2.56E-03 Avanti Polar Lipids 2/16/2013
Brain PS (L-α-phosphatidylserine (Brain, Porcine)) 1280 500 mg 2.56 per mg 3.21E-03 mg/device 8.21E-03 Avanti Polar Lipids 2/16/2013
Biotin PE 2660 10 mg 266 per mg 4.60E-05 mg/device 0.0122 Avanti Polar Lipids 2/16/2013
Anti-Collagen I antibody (biotin) 362 100 ug 3.62 per ug 0.12 ug/device 0.434 Abcam 2/16/2013
Streptavidin 591 10 mg 59.1 per mg 0.0003 mg/device 0.0177 Sigma Aldrich 2/16/2013
Sigmacote 96.9 100 ml 0.969 per ml 5.4 ul/device 0.00523 Sigma Aldrich 2/16/2013
Triton X-100 155 3785 ml 0.0409 per ml 0.002 ml/device 8.19E-08 Sigma Aldrich 2/16/2013
Bio Beads SM-2 425 100 g 4.25 per g 0.8 mg/device 0.00340 Bio-Rad 2/16/2013
PDMS 2 1 kg 2 per kg 0.0338 kg/device 0.0676 Alibaba 2/17/2013
Plastic Cartridge 0.05 1 unit 0.05 per unit 1 unit/device 0.05 assume 2/17/2013
Pipette Tips 193 3840 tips 0.0503 per tip 5 tips/device 0.251 Sigma Aldrich 2/17/2013
glass slides (1"x3") 86.4 1440 slides 0.06 per slide 1 slide/device 0.06 Alibaba 2/19/2013
KMPR 1050 4138 4 L 1.03 per mL 1 mL/cast 0.05 MicroChem 2/19/2013
Total Cost 1.16
COSTS
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9.3.2 Costing the Processing Unit 
The final design and construction of the Microfluidic Multi-Surface Coagulation Assay 
processing unit will be contracted to an outside company. To judge the cost of construction of a 
processing unit, it was treated as fabricated equipment. As defined by Seider et al., fabricated 
equipment are devices that are manufactured from its individual parts and put together in the 
lab12. The contracted company would purchase the individual parts from distributors and 
combine them within a casing. The list of parts and the costs of the parts is shown in Table 9.2. 
The cost to manufacture the devices was assumed to be 1.0x the total cost of individual internal 
parts. The total cost of parts was $10,750 and the total cost to produce a processing unit 
(including markup) is $21,500. 
In pricing the processing unit, the prices of the competitors discussed in Chapter 3 were 
considered. We also considered our company’s sales model in pricing the unit. The main profit 
driver for the company comes from the sales of the chips, which the customer will need to 
continually purchase. Taking these concerns into account, the sticker price for the processing 
unit is $30,000. As with the competition, this price is subject to change based on the contract 
negotiated between the customer and the sales department. 
Processing Unit 
Component Number of Components 
Estimated Cost per 
Unit 
Liquid Handler 1 $1000 
Syringe Pump 1 $1000 
Mobile Tray Handler 1 $4000 
LEDs 2 $500 
CCD Camera 1 $1000 
Injection Molded Case 1 $1000 
Computer + Software 1 $750 
 Parts Total $10,750 
Manufacturing Estimated Cost is 1.0*Parts Total $10,750 
 Total Cost $21,500 
Table 9.3: Costing of components for the Processing Unit. 
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9.4 Operating Assumptions 
Sales, General, and Administration Costs are overhead for the business. As shown in 
Appendix 13.3, this calculated amount is a percentage of revenues. The cost of performing 
clinical trials and filing FDA approval were accounted for in the “miscellaneous” fixed costs. It 
is also important to note that the financial analysis used percentages and hourly wages to 
calculate the overall costs of employees in the manufacturing facility. To bring the estimate as 
close as possible to that shown in Chapter 7, the weighted average of the employee’s hourly 
salaries was used. We are also working under the assumption that all customers will pay the 
same amount for the device. The projected market lifetime for this product is ten years. We 
expect new technologies will enter the market and produce new devices.  
9.5 Inventory, Working Capital and PP&E 
 Inventory, Working Capital, and Plant, Property, and Equipment costs can all be found 
in the Appendix section 13.3. Inventory costs were calculated based on the number of chips 
required per year (one million). The working capital is determined based on current liabilities 
and current assets. Current assets are the total cash reserves, the value of the inventory, and the 
accounts receivable. We are planning on having 30 days of cash reserves as well as 30 days of 
accounts receivable. Having 30 days of cash reserves is equivalent to having 8.33% (1/12 of a 
year) of the cost of manufacturing. Similarly the 30 days of accounts receivable means having 
8.33% of the annual sales of the product. We also plan on holding seven days (1.92% of annual 
sales) of chip inventory. The current liabilities are the accounts payable is the money owed to 
vendors. We are planning on keeping 30 days of accounts payable, which amounts to 9.1% of 
raw material costs. The plant, property, and equipment costs refer to the purchasing and 
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maintenance capital expenditures. Since the plant is being leased, this cost only refers to the 
price and maintenance of manufacturing equipment.12 
9.6 Income Statement and Cash Flow 
 The income statement shows the net income created by the Microfluidic Multi-Surface 
Coagulation Assay after taking into account cost of goods sold, indirect costs, and taxes. The 
cost of goods sold is a compilation of the direct costs associated with the production of goods. 
The indirect costs are the costs not directly related to the manufacture of the device like facility, 
administration, and other fixed and variable costs. The tax for the device is what is paid to the 
government and is found at a rate of 37%.12 
 The cash flow is another important feature of the economic analysis. The cash flow 
allows investors to observe the cash going into the company and leaving the company. It takes 
into account all costs including depreciation. The cash flow is defined as “the net passage of 
money into or out of a company due to an investment.” 12 
9.7 Valuation, Returns, Payback Period 
The company was valuated as having a 2013 NPV of $176,195,600 and an IRR of 
247%. These values were found using the Discounted Cash Flow model. The net present value 
is calculated for 10 years of production. The cash flow over the lifetime of the company was 
calculated and these values were discounted to the present value. These values are under the 
assumption that we would sell our cartridges at $100 per unit. With the different costs involved 
in the set up to production, it is important to look at how long it would take for the investors to 
realize profit on their investment. This time until their investment is repaid is known as the 
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Payback Period. Looking at Appendix 13.3, the payback period for the Microfluidic Multi-
Surface Coagulation Assay occurs within the first year of production. 
9.8 Sensitivity Analysis 
 A sensitivity analysis was performed to see how the IRR changed as an effect of sales 
price and variable costs. Sensitivity analyses show how a calculated value like the IRR is 
affected by parameters that can be controlled. In this study we look at how different chip prices 
and different variable costs affect the IRR. Chip price and variable costs were chosen because 
they are values that the company decides on depending on how the market is fairing. The base 
price was set at $100/unit and the base variable cost was calculated to be $17.8 M/yr. As 
mentioned before, the IRR at the base values is 247%. The two variables were allowed to 
deviate +/- 50%. The best case scenario is a price of $150 and very minimal variable costs 
which would allow investors to realize a 293% IRR. The worst case scenario for this analysis 
occurs at a sales price of $50 with very high variable costs, which results in an IRR of 112.7%. 
These numbers are summarized in Table 9.3, below.
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Table 9.3: Sensitivity Analysis testing the effect of Product Price and Variable Costs on IRR 
Microfluidic Multi-Surface Coagulation Assay  Cummings, Vuppala, Wang 
 
113 
 
9.9 Expansion 
As stated in Section 9.1, the market share captured by the Microfluidic Multi-Surface 
Coagulation Assay is projected to increase over the first five years. This would introduce an 
expansion cost. There are multiple ways to expand the facilities. The first method would be to 
construct a second process line. Another method would be to introduce a second shift for the 
manufacture of the devices. This would double the number of devices produced by the 
manufacturing facility. Since we are estimating that market expansion will end at around 25%, 
we would be able to run three shorter shifts to accommodate demand as well as manufacturing 
inefficiencies such as downtime between shifts. 
9.10 Summary 
 In summary the overall financial analysis shows that the Microfluidic Multi-Surface 
Coagulation Assay has the potential for profit generation. With an IRR, ROI, and NPV of 
247%, 442.4%, and $176,195,600 respectively this project has strong economic feasibility. The 
data and calculations for these values can be found in the Appendix, Section 13.3. 
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Chapter 10: Recommendations and Conclusions 
 The Microfluidic Multi-Surface Coagulation Assay utilizes microfluidic technology to 
create a faster and more efficient product to detect blood coagulation. It will allow healthcare 
professionals to achieve more detailed information from a single sample in less time than any of 
our competitors. There are still ways that the µMCA can be improved to fulfill its potential and 
adapt as the market grows and changes.  
  An advantage of our device is its potential for flexibility. The four clotting surfaces can 
be changed with relative ease in the manufacturing process and placed at any point along the 4 
cm length of the flow channels. Additionally, different reagents and dyes can be added to the 
cartridge so blood clotting under completely different conditions can be tested without changing 
the basic architecture of our device. This greatly widens the potential application for this 
product. For example, magnesium and zinc buffer solutions can also be mixed with citrated 
whole blood to initiate clotting but has not been readily studied. In order to successfully 
customize the device, the diffusion of these new buffers must be studied to determine the length 
along the channel to place the clotting surfaces. Furthermore, with customizations, although the 
behavior of the flows can be modeled, they will still need to be tested with prototypes to ensure 
that the device performs the tests with accuracy and precision. 
 Both testing of the product and profits can also be improved if the manufacturing of the 
processing unit were to occur in-house. In the current plan, the manufacturing of the processing 
unit is outsourced to an electronic equipment supplier. If instead, the processing units were 
incorporated into our manufacturing division, it would make it easier to make alterations to its 
design and make the units more available to test new designs of the device, instead of relying on 
an outside supplier.  
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 As stated in Chapter 3, the United States encompasses approximately 40 percent of the 
market for blood-related products. After our target market penetration has been achieved, we 
can adjust our marketing strategy and business plan in order to make the Microfluidic Multi-
Surface Coagulation Assay available to the international market. This would require testing to 
ensure that the product meets the standards of other countries and further understanding of the 
current state of the market for testing of blood coagulation.   
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Chapter 13: Appendix 
 
13.1 MSDS Reports 
 PDFs of material safety data sheets are excluded from this report for brevity, but are 
available upon request by emailing Elizabeth Cummings, e.m.cummings2@gmail.com. 
Chemicals used throughout the report and experiments are listed below, along with sources. 
PDFs for individual chemicals and reagents are available on the provider's website. 
Bovine Serum Albumen: Santa Cruz Biotechnology, Inc.; Santa Cruz, CA 
Calcium Chloride: Fisher Scientific; Fair Lawn, NJ 
Collagen: American Biochemical and Pharmaceutical Ltd.; Surry, UK 
HEPES Buffered Saline: Sigma Aldrich; St. Louis, MO 
Kaolin: Sigma Aldrich; St. Louis, MO 
KMPR 1050: MicroChem; Newton, MA 
L-α-phosphatidylcholine (Heart, Bovine): Avanti Polar Lipids; Alabaster, AL 
L-α-phosphatidylserine (Brain, Porcine) (sodium salt): Avanti Polar Lipids; Alabaster, AL 
1-oleoyl-2-(12-biotinyl(aminododecanoyl))-sn-glycero-3-phosphoethanolamine:Avanti Polar 
Lipids; Alabaster, AL 
Magnesium Chloride: Fisher Scientific; Fair Lawn, NJ 
Methyl Cellulose: Sigma Aldrich; St. Louis, MO 
PDMS: Acros Organics BVBA; Geel, Belgium 
Rabbit Polyclonal to Collagen I (Biotin): Abcam Inc.; Cambridge, MA 
Recombinant Human Tissue Factor Apoprotein: American Diagnostica Inc.; Stamford, CT 
Sigmacote®: Sigma Aldrich; St. Louis, MO 
Streptavidin from Streptomyces Avidinii: Sigma Aldrich; St. Louis, MO 
Triton™ X-100: Sigma Aldrich; St. Louis, MO 
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Zinc Chloride: Fisher Scientific; Fair Lawn, NJ 
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13.2 Market Analysis 
The breakdown of the target markets for the Microfluidic Multi-Surface Coagulation 
Assay can be separated into four categories. First are victims of strokes and heart attacks. 
Second are people who are in need of anti-clotting drugs, and the third category is clinical trials, 
and though clinical trials can range from hundreds to tens of thousands of participants, a 
conservative estimate of 200 patients per trial was used. The final category is trauma cases 
including emergency room visits for injuries and motor vehicle accidents. Not all patients in any 
of these categories will need the Microfluidic Multi-Surface Coagulation Assay, so 20 percent 
of the total was used in our calculations. With these calculations, the total market size is 
estimated to be 11.4 million, and we decided to use 10 million as a more conservative estimate. 
Table 13.1 shows the numerical breakdown used to achieve approximately 10 million total 
market size for the Microfluidic Multi-Surface Coagulation Assay.  
  Number of Individuals per Year 
Heart Attack 935,000 
Stroke 795,000 
Anti-Clotting Drugs 5,800,000 
Clinical Trials 379,000 
Emergency Room - Injury 45,200,000 
Emergency Room - Motor Vehicle Accident 4,047,000 
Total 57,156,000 
20% of Total 11,431,200 
 
 
  
Table 13.1 Breakdown of the markets for the Microfluidic Multi-Surface 
Coagulation Assay 
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13.3 Financial Analysis 
13.3.1 Summary of Inputs and Chronology of Events for $100 chip 
General Information               
 
Process Title: µMCA Manufacture Process 
    
 
Product: µMCA 
      
 
Plant Site Location: Mid-Atlantic Region 
     
 
Site Factor: 1.00 
      
 
Operating Hours per Year: 2640 
      
 
Operating Days Per Year: 110 
      
 
Operating Factor: 0.3014 
      
         
         Product Information               
This Process will Yield 
       
  
387 Unit of µMCA per hour 
    
  
9,288 Unit of µMCA per day 
    
  
1,021,680 Unit of µMCA per year 
    
         
 
Price $100.00  /Unit 
     
         Chronology               
  
Distribution of Production  Depreciation Product Price 
Year Action Permanent Investment Capacity 5 year MACRS 
  2013 Design 
 
0.0% 
    2014 Construction 100% 0.0% 
    2015 Construction 0% 0.0% 
    2016 Production 0% 49.0% 20.00% 
 
$100.00  
 2017 Production 0% 73.5% 32.00% 
 
$102.40  
 2018 Production 
 
98.0% 19.20% 
 
$104.86  
 2019 Production 
 
98.0% 11.52% 
 
$107.37  
 2020 Production 
 
98.0% 11.52% 
 
$109.95  
 2021 Production 
 
98.0% 5.76% 
 
$112.59  
 2022 Production 
 
98.0% 
  
$115.29  
 2023 Production 
 
98.0% 
  
$118.06  
 2024 Production 
 
98.0% 
  
$120.89  
 2025 Production 
 
98.0% 
  
$123.79  
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Equipment Costs             
        Equipment Description 
    
Bare Module Cost 
        Oven x2 
  
Process Machinery 
 
$89,600 
 Liquid Handling Robot x4 
 
Process Machinery 
 
$360,000 
 Robot Handler x2 
 
Process Machinery 
 
$90,000 
 Oxygen Plasma Machine x2 
 
Process Machinery 
 
$180,000 
 Foil Sealing Machine x2 
 
Process Machinery 
 
$22,500 
 Ink-Jet Printer x2 
 
Process Machinery 
 
$280,000 
 Packaging x2 
 
Process Machinery 
 
$95,884 
 Foundry Machine x2 
 
Process Machinery 
 
$80,000 
  
Total 
     
$1,197,984 
  
         Raw Materials               
 
Raw Material: Unit: Required Ratio: 
 
Cost of Raw 
Material: 
 1 All Raw Materials Unit: 1 Unit: per Unit of µMCA $1.162 per Unit: 
 
 
              
 
 
Total Weighted 
Average: 
    
$1.162 
per Unit of 
µMCA 
Utilities                 
 
Utility: Unit: Required Ratio 
 
Utility 
Cost 
  
1 High Pressure Steam lb 0 lb per Unit of µMCA 
$0.000E+0
0 per lb 
 
2 Low Pressure Steam lb 0 lb per Unit of µMCA 
$0.000E+0
0 per lb 
 
3 Process Water gal 0 gal per Unit of µMCA 
$0.000E+0
0 per gal 
 
4 Cooling Water lb 0 lb per Unit of µMCA 
$0.000E+0
0 per lb 
 5 Electricity kWh 0.07 kWh per Unit of µMCA $0.060 per kWh 
 
 
 
              
 
 
Total Weighted 
Average: 
    
$4.200E-03 
per Unit of 
µMCA 
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13.3.2 Variable Cost 
Utilities                 
 
Utility: Unit: Required Ratio 
 
Utility 
Cost 
  
1 High Pressure Steam lb 0 
lb per Unit of 
µMCA 
$0.000E
+00 per lb 
 
2 Low Pressure Steam lb 0 
lb per Unit of 
µMCA 
$0.000E
+00 per lb 
 
3 Process Water gal 0 
gal per Unit of 
µMCA 
$0.000E
+00 per gal 
 
4 Cooling Water lb 0 
lb per Unit of 
µMCA 
$0.000E
+00 per lb 
 
5 Electricity kWh 0.07 
kWh per Unit of 
µMCA $0.060 per kWh 
 
 
              
 
 
Total Weighted Average: 
    
$4.200E-
03 
per Unit of 
µMCA 
Variable Costs               
 
General Expenses: 
       
   
Selling / Transfer Expenses: 3.00% of Sales 
   
   
Direct Research: 8.00% of Sales 
   
   
Allocated Research: 2.00% of Sales 
   
   
Administrative Expense: 2.00% of Sales 
   
   
Management Incentive Compensation: 1.25% of Sales 
   Working Capital               
         
 
Accounts Receivable 
 
 30 Days 
   
 
Cash Reserves (excluding Raw 
Materials)  30 Days 
   
 
Accounts Payable 
 
 30 Days 
   
 
µMCA Inventory 
 
 7 Days 
   
 
Raw Materials 
 
 7 Days 
   Total Permanent 
Investment               
         
   
Cost of Site Preparations: 5.00% of Total Bare Module Costs 
 
   
Cost of Service Facilities: 5.00% of Total Bare Module Costs 
 
   
Allocated Costs for utility plants and 
related facilities: $0  
  
   
Cost of Contingencies and Contractor 
Fees: 18.00% 
of Direct Permanent 
Investment 
 
   
Cost of Land: 0.00% of Total Depreciable Capital 
 
   
Cost of Royalties: $0  
    
   
Cost of Plant Start-Up: 10.00% of Total Depreciable Capital 
  13.3.3 Fixed Costs 
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Fixed Costs               
 
Operations 
       
   
Operators per Shift: 8 (assuming 1 shifts) 
  
   
Direct Wages and Benefits: $30  /operator hour 
  
   
Direct Salaries and Benefits: 15% of Direct Wages and Benefits 
 
   
Operating Supplies and Services: 6% of Direct Wages and Benefits 
 
   
Technical Assistance to 
Manufacturing: $0.00 
per year, for each Operator per 
Shift 
 
   
Control Laboratory: $0.00 
per year, for each Operator per 
Shift 
 
         
 
Maintenance 
       
   
Wages and Benefits: 
15.00
% of Total Depreciable Capital 
 
   
Salaries and Benefits: 25% 
of Maintenance Wages and 
Benefits 
 
   
Materials and Services: 100% 
of Maintenance Wages and 
Benefits 
 
   
Maintenance Overhead: 5% 
of Maintenance Wages and 
Benefits 
 
         
 
Operating 
Overhead 
       
         
   
General Plant Overhead: 7.10% 
of Maintenance and Operations 
Wages and Benefits 
   
Mechanical Department Services: 2.40% 
of Maintenance and Operations 
Wages and Benefits 
   
Employee Relations Department: 5.90% 
of Maintenance and Operations 
Wages and Benefits 
   
Business Services: 7.40% 
of Maintenance and Operations 
Wages and Benefits 
         
         
 
Property Taxes and 
Insurance 
      
   
Property Taxes and Insurance: 2% of Total Depreciable Capital 
 
         
 
Straight Line 
Depreciation 
      
 
Direct Plant: 
8.00
% of Total Depreciable Capital, less 1.18 times the Allocated Costs  
 
     
for Utility Plants and Related 
Facilities 
 
Allocated Plant: 
6.00
% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities 
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Other Annual Expenses 
      
   
Rental Fees (Office and 
Laboratory Space): 
$500,0
00 
    
   
Licensing Fees: $0 
    
   
Miscellaneous: 
$1,000,
000 
    
         
 
Depletion 
Allowance 
       
   
Annual Depletion Allowance: $0 
                      
 
13.3.4 Fixed Cost Summary 
Fixed Cost Summary           
       
       
 
Operations 
     
       
  
Direct Wages and Benefits 
  
 $                 499,200  
  
Direct Salaries and Benefits 
 
 $                   74,880  
  
Operating Supplies and Services 
 
 $                   29,952  
  
Technical Assistance to Manufacturing 
 
 $                           -    
  
Control Laboratory 
  
 $                           -    
       
  
Total Operations 
  
 $                 604,032  
       
 
Maintenance 
    
  
Wages and Benefits 
  
 $                 233,247  
  
Salaries and Benefits 
  
 $                   58,312  
  
Materials and Services 
  
 $                 233,247  
  
Maintenance Overhead 
  
 $                   11,662  
       
  
Total Maintenance 
  
 $                 536,469  
       
 
Operating Overhead 
    
       
  
General Plant Overhead: 
  
 $                   61,460  
  
Mechanical Department Services: 
 
 $                   20,775  
  
Employee Relations Department: 
 
 $                   51,073  
  
Business Services: 
  
 $                   64,057  
       
  
Total Operating Overhead 
 
 $                 197,366  
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Property Taxes and Insurance 
   
       
  
Property Taxes and Insurance: 
 
 $                   31,100  
       
 
Other Annual Expenses 
    
       
  
Rental Fees (Office and Laboratory Space):  $                 500,000  
  
Licensing Fees: 
  
 $                           -    
  
Miscellaneous: 
  
 $              1,000,000  
       
  
Total Other Annual Expenses 
 
 $              1,500,000  
       
 
Total Fixed Costs 
   
 $              2,868,967  
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13.3.5 Investment Summary 
Investment Summary           
        Bare Module Costs 
      
 
Fabricated Equipment 
   
 $                           -    
 
 
Process Machinery 
   
 $              1,197,984  
 
 
Spares 
    
 $                           -   
 
 
Storage 
    
 $                           -   
 
 
Other Equipment 
   
 $                           -    
 
 
Catalysts 
    
 $                           -    
 
 
Computers, Software, Etc. 
  
 $                           -    
 
        
 
Total Bare Module Costs: 
   
 $              1,197,984  
        Direct Permanent Investment 
     
        
 
Cost of Site Preparations: 
  
 $                   59,899  
 
 
Cost of Service Facilities: 
  
 $                   59,899  
 
 
Allocated Costs for utility plants and related facilities:  $                           -    
 
        
 
Direct Permanent Investment 
   
 $              1,317,782  
        
        Total Depreciable Capital 
     
        
 
Cost of Contingencies & Contractor Fees 
 
 $                 237,201  
 
        
        
 
Total Depreciable Capital 
   
 $              1,554,983  
        Total Permanent Investment 
     
        
 
Cost of Land: 
   
 $                           -    
 
 
Cost of Royalties: 
   
 $                           -    
 
 
Cost of Plant Start-Up: 
   
 $                 155,498  
 
        
 
Total Permanent Investment - Unadjusted 
  
$              1,710,482  
 
Site Factor 
     
1.00 
 
Total Permanent Investment 
   
 $              1,710,482  
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13.3.6 Working Capital 
Working Capital               
         
      
2015 2016 2017 
   
Accounts Receivable 
 
 $              4,114,711   $              2,057,356   $                2,057,356  
   
Cash Reserves 
 
 $                   55,307   $                   27,653   $                     27,653  
   
Accounts Payable 
 
 $                  (47,986)  $                 (23,993)  $                    (23,993) 
   
µMCA Inventory 
 
 $                 960,099   $                 480,050   $                   480,050  
   
Raw Materials 
 
 $                   11,156   $                     5,578   $                       5,578  
   
Total 
  
 $              5,093,288   $              2,546,644   $                2,546,644  
         
   
Present Value at 15% 
 
 $              3,851,257   $             1,674,460   $                1,456,052  
         
 
Total Capital Investment 
   
 $              8,692,250  
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13.3.7 Cash Flow 
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13.3.8 Profitability Measures 
Profitability Measures         
        The Internal Rate of Return (IRR) for this project is 
 
247.32% 
       
 
The Net Present Value (NPV) of this project in 2013 is 
 
 $  176,195,600  
        
        ROI Analysis (Third Production Year) 
   
        
 
Annual Sales 
  
     104,988,295  
  
 
 
Annual Costs 
  
      (21,293,301) 
  
 
 
Depreciation 
  
           (136,839) 
  
 
 
Income Tax 
  
      (30,916,517) 
  
 
 
Net Earnings 
  
       52,641,638  
  
 
 
Total Capital Investment        11,897,057  
   
 
ROI 
  
442.48% 
  
 
 
13.3.9 Sensitivity Analysis  
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13.3.10 Summary of Inputs and Chronology of Events for $30 chip 
General Information               
 
Process Title: µMCA Manufacture Process 
    
 
Product: µMCA 
      
 
Plant Site Location: Mid-Atlantic Region 
     
 
Site Factor: 1.00 
      
 
Operating Hours per Year: 2640 
      
 
Operating Days Per Year: 110 
      
 
Operating Factor: 0.3014 
      
         
         Product Information               
This Process will Yield 
       
  
387 Unit of µMCA per hour 
    
  
9,288 Unit of µMCA per day 
    
  
1,021,680 Unit of µMCA per year 
    
         
 
Price $30.00  /Unit 
     
         Chronology               
  
Distribution of Production  Depreciation Product Price 
Year Action Permanent Investment Capacity 5 year MACRS 
  2013 Design 
 
0.0% 
    2014 Construction 100% 0.0% 
    2015 Construction 0% 0.0% 
    2016 Production 0% 49.0% 20.00% 
 
$30.00  
 2017 Production 0% 73.5% 32.00% 
 
$30.72  
 2018 Production 
 
98.0% 19.20% 
 
$31.46  
 2019 Production 
 
98.0% 11.52% 
 
$32.21  
 2020 Production 
 
98.0% 11.52% 
 
$32.99  
 2021 Production 
 
98.0% 5.76% 
 
$33.78  
 2022 Production 
 
98.0% 
  
$34.59  
 2023 Production 
 
98.0% 
  
$35.42  
 2024 Production 
 
98.0% 
  
$36.27  
 2025 Production 
 
98.0% 
  
$37.14  
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13.3.11 Variable Cost Summary for $30 Chip 
Variable Cost Summary           
 
Variable Costs at 100% Capacity: 
   
       
 
General Expenses 
    
       
  
Selling / Transfer Expenses: 
 
 $                 919,512  
  
Direct Research: 
  
 $              2,452,032  
  
Allocated Research: 
  
 $                 613,008  
  
Administrative Expense: 
  
 $                 613,008  
  
Management Incentive Compensation: 
 
 $                 383,130  
       
 
Total General Expenses 
   
 $              4,980,690  
       
 
Raw Materials $1.162000 per Unit of µMCA $1,187,192  
       
 
Byproducts $0.000000 per Unit of µMCA $0  
       
 
Utilities 
 
$0.004200 per Unit of µMCA $4,291  
       
 
Total Variable Costs 
   
 $              6,172,173  
 
 
13.3.12 Profitability Measures for $30 Chip 
Profitability Measures         
        
The Internal Rate of Return (IRR) for this project is  137.61% 
        
The Net Present Value (NPV) of this project in 2013 is   $    44,924,000  
        
ROI Analysis (Third Production Year)    
        
 Annual Sales   31,496,488    
 Annual Costs   (9,350,882)    
 Depreciation   (136,839)    
 Income Tax   (8,143,244)    
 Net Earnings   13,865,523    
 Total Capital Investment 4,792,322    
 ROI   289.33%    
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13.3.13 Profitability Measures for $100 Chip 2x Expansion 
Profitability Measures         
        The Internal Rate of Return (IRR) for this project is 
 
312.04% 
       
 
The Net Present Value (NPV) of this project in 2013 is 
 
 $  359,143,900  
        
        ROI Analysis (Third Production Year) 
   
        
 
Annual Sales 
 
 209,976,589 
   
 
Annual Costs 
 
 (40,348,894) 
   
 
Depreciation 
 
 (136,839) 
   
 
Income Tax 
 
 (62,711,617) 
   
 
Net Earnings 
 
 106,779,240 
   
 
Total Capital Investment 22,032,561 
   
 
ROI 
 
 484.64% 
    
13.3.14 Variable Cost Summary for $100 Chip 2x Expansion 
Variable Cost Summary           
 
Variable Costs at 100% Capacity: 
   
       
 
General Expenses 
    
       
  
Selling / Transfer Expenses: 
 
 $              6,130,080  
  
Direct Research: 
  
 $            16,346,880  
  
Allocated Research: 
  
 $              4,086,720  
  
Administrative Expense: 
  
 $              4,086,720  
  
Management Incentive Compensation: 
 
 $              2,554,200  
       
 
Total General Expenses 
   
 $            33,204,600  
       
 
Raw Materials $1.162000 per Unit of µMCA $2,374,384  
       
 
Byproducts $0.000000 per Unit of µMCA $0  
       
 
Utilities 
 
$0.004200 per Unit of µMCA $8,582  
       
 
Total Variable Costs 
   
 $            35,587,566  
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13.3.15 Fixed Cost Summary for $100 Chip 2x Expansion 
Fixed Cost Summary           
       
       
 
Operations 
     
       
  
Direct Wages and Benefits 
  
$                 998,400  
  
Direct Salaries and Benefits 
 
 $                 149,760  
  
Operating Supplies and Services 
 
 $                   59,904  
  
Technical Assistance to Manufacturing 
 
 $                           -    
  
Control Laboratory 
  
 $                           -    
       
  
Total Operations 
  
 $              1,208,064  
       
 
Maintenance 
    
  
Wages and Benefits 
  
 $                 233,247  
  
Salaries and Benefits 
  
 $                   58,312  
  
Materials and Services 
  
 $                 233,247  
  
Maintenance Overhead 
  
 $                   11,662  
       
  
Total Maintenance 
  
 $                 536,469  
       
 
Operating Overhead 
    
       
  
General Plant Overhead: 
  
 $                 102,220  
  
Mechanical Department Services: 
 
 $                   34,553  
  
Employee Relations Department: 
 
 $                   84,943  
  
Business Services: 
  
 $                 106,539  
       
  
Total Operating Overhead 
 
 $                 328,256  
       
 
Property Taxes and Insurance 
   
       
  
Property Taxes and Insurance: 
 
$                   31,100  
       
 
Other Annual Expenses 
    
       
  
Rental Fees (Office and Laboratory Space): $                 500,000  
  
Licensing Fees: 
  
 $                           -    
  
Miscellaneous: 
  
 $              1,000,000  
       
  
Total Other Annual Expenses 
 
 $              1,500,000  
       
 
Total Fixed Costs 
   
 $              3,603,889  
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13.3.16 Market Projections   
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13.4 Lab Protocols 
 
13.4.1 Collagen Surfaces 
Making a Collagen Surface 1 
Reagents 
●  Sigmacote (Sigma) 
● Equine Type I Collagen Fibrils (Chrono-Par, Chrono-Log, Havertown, PA) (1 mg/mL) 
●  .5% bovine serum albumen in HEPES-buffered saline solution 
Instructions 
1. Treat surface with Sigmacote2 
● Cover clean and dry surface with Sigmacote 
● Allow to dry in a hood, and rinse with water 
2. Allow Collagen Solution (1 mg/mL) to rest on glass surface for 30 minutes. 
3. Wash surface with .5% BSA in HBS. 
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13.4.2 Tissue Factor Liposomes 
Making Tissue Factor Liposomes47 
Reagents 
● Phosphatidylcholine (PC); Avanti Polar Lipids, Alabaster, AL 
●  Phosphatidylserine (PS); Avanti Polar Lipids, Alabaster, AL 
● Biotinylated phosphatidylethanolamine; Avanti Polar Lipids, Alabaster, AL 
● 4 mM Triton X-100 in HBS; Fisher Scientific, Fair Lawn, NJ 
● Bio-Beads SM-2; BioRad Laboratories 
● Purified Recombinant Tissue Factor (1.3 mg/mL)3; American Diagnostica Inc, 
Stamford, CT 
● HBS 
Instructions 
1. Mix 79% PC, 20% PS and 1% biotinylated phosphatidylethanolamine1.  
2. Dry in glass tubes under nitrogen and place in high vacuum for one hour (to remove residual 
chloroform) 
3. Resuspend in HBS, vortex thoroughly 
4. Wash Bio-Beads SM-2 in methanol4 
● Add 200 mL of methanol to 30g Bio-Beads SM-2, stir for 15 min.  
● Collect beads on sintered glass funnel, wash with 500 mL of methanol. 
● ((Immediately wash with 1000 mL water, wash in chromatography column with another 
2000mL water.)) Store in HBS until required. 
● Immediately before using, place beads in weigh dish, remove excess liquid by 
aspiration, and weigh beads. Do not let beads dry prior to use. 
5. Dissolve a total of 2.6 μmol phospholipid (1.59 mg pC, .43 mg PS, .023 mg biotinylated 
phosphatidylethanolamine) in 993.8 μL of 3 mM Triton X-100 in HBS. Add 6.2 μL 
recombinant tissue factor (to achieve a 1:10000 protein to lipid ratio) 
6. To remove detergent, add 50 mg Bio-Beads SM-2 to above solution in an Eppendorf tube. 
Mix gently for 90 min at room temperature at 20 rpm on a tube rotator. 
7. Add 350 mg Bio-Beads SM-2, rotate for an additional 90 minutes. 
8. Allow beads to settle by gravity for 2 min. 
9. Remove supernatant which contains the rTF liposomes and store at -80 °C until use. 
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13.4.3 Tissue-Factor Collagen Surfaces 
Making a Tissue-Factor Collagen Surface2 
Reagents 
●  Collagen Surface 
●  Biotinylated polyclonal antibody against collagen type 1 (40 μg/mL); Abcam, 
Cambridge, MA 
●  .5% bovine serum albumen in HEPES-buffered saline solution 
● Streptavidin (100 μg/mL); Sigma 
● Tissue-Factor Liposomes 
Instructions 
1. Perfuse collagen surface with biotinylated polyclonal antibody against collagen type 1 (40 
μg/mL). Allow to rest for 5 minutes 
2. Wash surface with BSA. 
3. Fill channel with streptavidin immediately. Allow to rest for 5 minutes 
4. Fill channel with TF-liposomes. Allow to incubate for 1 hour. 
5. Rinse with BSA. 
6. Fill devices with BSA for at least 30 minutes before use with blood.2 
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13.4.4 Kaolin-Liposome Mixture 
Mixing Liposomes with Kaolin 
Reagents 
● Kaolin; Sigma Aldrich 
● Phosphatidylcholine (PC); Avanti Polar Lipids, Alabaster, AL 
● Phosphatidylserine (PS); Avanti Polar Lipids, Alabaster, AL 
● Biotinylated phosphatidylethanolamine; Avanti Polar Lipids, Alabaster, AL 
● HBS 
Instructions 
1. Mix 80% PC, 20% PS2. 
2. Dry in glass tubes under nitrogen and place in high vacuum for one hour (to remove residual 
chloroform) 
3. Resuspend in HBS, vortex thoroughly.  
4. Make a .1125M suspension of kaolin by mixing 25 mg of kaolin to a total volume of 1 mL in 
HBS. Make sure there are no pockets of unsuspended kaolin in the tube. 
5. Add 800 μL of the kaolin solution to 200 μL of liposome mixture.  
6. Vortex this solution thoroughly. 
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13.4.5 Kaolin-Liposome-Collagen Surface 
Making a Kaolin-Collagen Surface 
Reagents 
● Collagen Surface 
●  .5% bovine serum albumen in HEPES-buffered saline solution 
● Kaolin-Liposome solution, described above 
Instructions 
1. Perfuse collagen surface with kaolin-liposome solution. Allow to incubate for 30 minutes. 
2. Rinse surface with BSA. Surface is ready to use
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13.5  Labor Costs 
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13.6 Manufacturing Batch Sizing 
Total Devices 1000000   
Total Days of Operation  330   
Devices Per Day 3030.303   
1% quality testing 3060.912 30.60912 
1% failure 3091.83 30.9183 
Number of Batches a Day 6   
Number of Devices per 
Batch 515.3051   
Length 8 cm 
Width 4 cm 
Area 32 cm2 
Total Area per Batch 
16489.76 cm2 
1.648976 m2 
17.74942 ft2 
 
 
 
 
 
 
 
 
 
 
 
  
Table 13.3 Sizing of a single batch of devices 
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13.7 Ink Jet Printing Quote 
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13.8 Packaging Quote 
 
